(51) International Patent Classification 6 : A61K 39/395, C07K 16/00, 16/18, 16/28, 16/46, C12N 5/10, 5/16, 15/13, C12P 21/08	A1	(11) International Publication Number: **WO 95/34324** (43) International Publication Date: 21 December 1995 (21.12.95)

(54) Title: CROSS-REACTING MONOCLONAL ANTIBODIES SPECIFIC FOR E-SELECTIN AND P-SELECTIN

(57) Abstract

     The invention provides monoclonal antibodies that specifically bind to P-selectin and to E-selectin. Humanized monoclonal antibodies also are disclosed. Many of the antibodies block the functional interactions of P-selectin and E-selectin with their respective counterreceptors.

CROSS-REACTING MONOCLONAL ANTIBODIES
SPECIFIC FOR E-SELECTIN AND P-SELECTIN

BACKGROUND OF THE INVENTION

The ability of cells to adhere to one another plays a critical role in development, normal physiology, and disease processes such as inflammation. This ability is mediated by adhesion molecules, generally glycoproteins, expressed on cell membranes. Often, an adhesion molecule on one cell type will bind to another adhesion molecule expressed on a different cell type, forming a receptor counter-receptor pair. Three important classes of adhesion molecules are the integrins, selectins, and immunoglobulin (Ig) superfamily members (*see* Springer, *Nature* 346:425 (1990); Osborn, *Cell* 62:3 (1990); Hynes, *Cell* 69:11 (1992). These molecules are vital to the interaction of leukocytes and platelets with themselves and with the extracellular matrix and vascular endothelium.

The selectin family of receptors are so named because of their lectin-like domain and the selective nature of their adhesive functions. There are three known selectins, L-selectin (also known as LECAM-1, Mel-14 or LAM-1 or CD62L), E-selectin (also called ELAM-1 or CD62E) and P-selectin (also known as CD62, CD62P, GMP140 or PADGEM). The selectins are highly homologous, containing a 120 amino acid (aa) N-terminal lectin domain, an EGF-like domain, a variable number of multiple short consensus repeat (SCR) domains homologous to those found in complement regulatory proteins, followed by a transmembrane domain and short cytoplasmic tail. *See* Siegelman et al., *Science* 243:1165-1172 (1989); Lasky et al., *Cell* 56:1045-1055 (1989); Tedder et al., *J. Exp. Med.* 170:123-133 (1989); Johnson et al., *Cell* 56:1033-1044 (1989); Bevilacqua et al., *Proc. Natl. Acad. Sci. USA* 84:9238-9242 (1987), Bevilacqua et al., *Science* 243:1160-1165 (1989), Bevilacqua et al., *J. Clin. Invest.* 91:379-387 (1993), Camerini et al., *Nature* 280:496-498 (1989). The selectins

have overlapping but distinct specificities for counterreceptors. *See* Bevilacqua et al., *J. Clin. Invest.* 91:379-387 (1993); Feize, *Current Opinion in Struct. Biol.* 3:701-710 (1993); Berg et al., *Biochem. Biophys. Res. Comm.* 184:1048-1055 (1992); Foxall et al., *J. Cell Biol.* 117:895-902 (1992); Larsen et al., *J. Biol. Chem.* 267:11104-11110 (1992); Polley et al., *Proc. Natl. Acad. Sci. USA* 88:6224-6228 (1991) (each of which is incorporated by reference in its entirety for all purposes).

P-selectin is constitutively expressed by both platelets and endothelial cells where it is stored in α-granules or Weibel-Palade bodies for rapid (seconds to minutes) translocation to the cell surface upon activation by, for example, thrombin or histamine (McEver et al., *J. Biol. Chem.* 250:9799-9804 (1984); Hsu-Lin et al., *J. Biol. Chem.* 264:8121-9126 (1984)). E-selectin is expressed by activated endothelial cells (*e.g.*, after TNF-α or IL-1 stimulation for 6-8 hr). Its expression is controlled at the transcriptional level (Bevilacqua et al., 1987, *supra*; Bevilacqua et al., 1989, *supra*). P-selectin and E-selectin both bind to neutrophils and monocytes (Larsen et al., *Cell* 59:305-312 (1989); Johnston et al., *Cell* 56:1033-1044 (1989); Bevilacqua et al., 1987, *supra*; Bevilacqua et al., 1989, *supra*), as well as subsets of lymphocytes (Picker et al., *Nature* 349:796-799 (1991); Shimizu et al., *Nature* 349:799-802 (1991); Moore et al., *BBRC* 186:173-181 (1992)). L-selectin is constitutively expressed by leukocytes, and mediates lymphocyte adhesion to peripheral lymph node high endothelial venules (HEV) (Gallatin et al., *Nature* 304:30-34 (1983); Berg et al., *Immunol. Rev.* 108:5-18 (1989); Berg et al., *J. Cell. Biol.* 114:343-349 (1991)), and neutrophil adhesion to cytokine-activated endothelial cells (Hallman et al., *Biochem. Biophys. Res. Comm.* 174:236-243 (1991); Smith et al., *J. Clin. Invest.* 87:609-618 (1991); Spertini et al., *J. Immunol.* 147:2565-2573 (1991)). L-selectin is a counter-receptor on neutrophils for both E-selectin and P-selectin (Kishimoto et al., *Blood* 78:805-811 (1990), Picker et al., *Cell* 66:921 (1991)),

although all three selectins probably have other counter-receptors as well.

E-selectin, P-selectin and L-selectin mediate leukocyte-endothelial cell and platelet-leukocyte adhesive interactions during inflammation (Bevilacqua et al., 1993, *supra*). All three selectins have been demonstrated to participate in an initial "rolling" interaction of leukocytes with activated endothelium (von Andrian et al., *Proc. Natl. Acad. Sci. USA* 88:7538-7542 (1991); Ley et al., *Blood* 77:2553-2555 (1991); Abassi et al., *J. Clin. Invest.* 92:2719-2730 (1993); Dore et al., *Blood* 82:1308-1316 (1993); Jones et al., *Biophys. J.* 65:1560-1569 (1993); Mayadas et al., *Cell* 74:541-554 (1993)). This initial interaction precedes CD18-integrin-mediated adhesion and subsequent migration of neutrophils through the endothelium and into inflamed tissue sites (Lawrence et al., *Cell* 65:859-873 (1991); von Andrian et al., *Am. J. Physiol.* 263:H1034-H1044 (1992)). Depending on the nature of inflammatory stimuli and time after initiation of inflammatory response, either E-selectin or P-selectin may be functionally dominant in promoting neutrophil-mediated tissue damage.

In principle, antibodies or other antagonists of the selectins could abort the adhesion process, thereby preventing neutrophils from binding to the endothelium and from extravasating into tissues. A substantial number of antibodies specific for one of the selectins have been reported. Some of these antibodies have been reported to block binding of selectins to counterreceptors *in vitro*. Some of the antibodies have also been reported to block selectin-mediated interactions in animal models *in vivo*. For example, antibodies to E-selectin have been reported to protect against neutrophil-mediated damage in an IgG complex model of lung injury in the rat (Mulligan et al., *J. Clin. Invest.* 88:1396 (1991)). Antibodies to P-selectin have been reported to protect against acute lung injury induced by intravenous injection of cobra venom factor (Mulligan et al., *J. Clin. Invest.* 90:1600-1607 (1992)), as well as in a rat model of systemic endotoxemia (Coughlan et al., *J. Exp. Med.* 179:329-

334 (1994)). Antibodies to P-selectin have also been reported
to be protective in a cat model of myocardial ischemia and
reperfusion injury (Weyrich et al., *FASEB J.* 7:A785 (1993)).

Although some antibodies against E-selectin and
5   P-selectin have shown blocking activity, many, if not most,
antibodies specific for E-selectin or P-selectin are
nonblocking (*see, e.g.*, Bevilacqua et al., 1989, *supra*; Erbe
et al., *J. Cell Biol.* 119:215-227 (1992)). That is, these
antibodies bind to epitopes in the extracellular domains of
10   E-selectin or P-selectin that do not directly participate in
counterreceptor binding or the subsequent cellular adhesion
process. The prevalence of nonblocking antibodies suggests
that only small regions of the extracellular domain
participate directly in binding or influence binding. Thus,
15   *de novo* screening of antibodies generated against E-selectin
or P-selectin would be expected to generate mainly nonblocking
antibodies.

Despite the large number of antibodies isolated to-
date against the three selectins, there have been few reports
20   of crossreacting antibodies that bind to more than one
selectin. Crossreacting antibodies might be capable of
aborting the inflammatory process at more than one level,
thereby providing more broadly useful therapeutic agents for
neutrophil-mediated inflammatory conditions than antibodies
25   specific for a single selectin. One antibody has been
reported to crossreact with human E-selectin and dog
L-selectin but not with the two selectins from the same
species (Abassi et al., *J. Immunol.* 147:2107-2115 (1991)). A
second antibody has been reported to crossreact with human
30   E-selectin and L-selectins (Jutila et al., *J. Exp. Med.*
175:1565-1573 (1992); WO/9324614). However, no antibody has
been isolated that binds to both P-selectin and E-selectin,
much less blocks the functions of both of these molecules.

Accordingly, there is a need for antibodies that
35   bind to both E-selectin and P-selectin, preferably so as to
block the capacity of both of these molecules to participate
in adhesion reactions with counterreceptors. The present
invention fulfills this and other needs.

SUMMARY OF THE INVENTION

The invention provides monoclonal antibodies that have a binding site that specifically binds to P-selectin and to E-selectin. For many such antibodies, specific binding of the antibody to the P-selectin inhibits binding of the P-selectin to a counterreceptor of P-selectin, and specific binding of the antibody to E-selectin inhibits binding of the E-selectin to a counterreceptor of E-selectin. Counterreceptors of E-selectin and P-selectin are expressed on the surface of cells such as HL-60 cells and neutrophils. Exemplary antibodies are designated 57C.29, 2C9.11 and 1D8.10. Many of the antibodies of the invention compete with an exemplified antibody for specific binding to P-selectin and to E-selectin. Some antibodies of the invention also specifically bind to L-selectin, whereas others do not. In one embodiment the antibody recognizes an epitope of E-selectin comprising amino acids Q_{21}, R_{22}, Y_{23}, T_{119}, and A_{120}. In another embodiment, the antibodies bind to the same epitope of E-selectin and/or P-selectin as antibody 5C7.29. In addition to intact antibodies, the invention also provides binding fragments such as Fab, Fab', $F(ab')_2$, Fv or single-chain antibodies.

Some of the antibodies of the invention are non-human, e.g., mouse, whereas others are humanized or human antibodies. A humanized antibody comprises a humanized heavy chain variable region and a humanized light chain variable region. The humanized light chain variable region can comprise complementarity determining regions (e.g., CDR1, CDR2, CDR3) having amino acid sequences from the light chain of a mouse, antibody selected from the group consisting of 5C7.29, 2C9.11 and 1D8.10, and having a variable region framework sequence substantially identical to a human light chain variable region framework sequence. The humanized heavy chain variable region can comprise complementarity determining regions (e.g., CDR1, CDR2 and CDR3) having amino acid sequences from the corresponding mouse antibody heavy chain, and having a variable region framework sequence substantially identical to a human heavy chain variable region framework

sequence.   The antibodies optionally contain constant regions substantially identical to human constant regions.

In particular embodiments of the humanized antibodies of this invention, the humanized light chain

5   variable region has a sequence substantially identical to the mature sequence depicted in Figure 8A [SEQ ID NO:5] and the humanized heavy chain variable region has a sequence substantially identical to the mature sequences depicted in Figure 8B [SEQ ID NO:8].   More particularly, this invention

10   provides humanized antibodies wherein (a) the humanized light chain variable region has the sequence: $X_1IX_2X_3$TQSPSS LSASVGDRVT ITCSASSSX$_{11}$P YX$_{12}$HWYQQKPG KAPKLLIYDT SNX$_{13}$X$_{14}$X$_{15}$GVPX$_4$R X$_7$SGSGSGTX$_5$X$_6$ TX$_8$TISSLQPE DX$_9$ATYYCX$_{16}$X$_{17}$W SSDPFTFGX$_{10}$G TKVEIK [SEQ ID NO:9], wherein X_1 = D or Q; X_2 = Q

15   or V; X_3 = M or L; X_4 = S or A; X_5 = S or D; X_6 = Y or F; X_7 = F or I; X_8 = L or F; X_9 = F, I or A; X_{10} = Q, G or S; X_{11} = V, I or L; X_{12} = M or L; X_{13} = any amino acid; X_{14} = any amino acid; X_{15} = S or T; X_{16} = Q, N or H; and X_{17} = Q, N or H; and (b) the humanized heavy chain variable region has the

20   sequence: X$_3$VQLVESGGG LVQPGGSLRL SCAASGFTFS SFGX$_7$HWVRQA PGKGLEWVX$_1$F ISSGSSTIYY X$_8$X$_9$X$_{10}$X$_{11}$X$_{12}$X$_{13}$RFTI SRDNX$_4$KNX$_5$LY LQMX$_2$SLRAED TAVYYCARPL PPFAYWGQGT LVTVSX$_6$ [SEQ ID NO:10]; wherein, X_1 = A or S; X_2 = N or T; X_3 = E, Q or D; X_4 = S, A or P; X_5 = T or S; X_6 = A or S; X_7 = M, I, V or L; X_8 = any

25   amino acid; X_9 = any amino acid; X_{10} = any amino acid; X_{11} = V, A, I, L, M or F; X_{12} = R, K or Q; and X_{13} = G, A, D, T or S. In certain embodiments of the aforementioned antibodies, the CDR regions of the light and heavy chain variable regions have the same amino acid sequence as the CDR sequences of Figure 8A

30   and 8B.   That is, in the human light chain variable region, X_{11} = V; X_{12} = M; X_{13} = L; X_{14} = A; X_{15} = S; X_{16} = Q; and X_{17} = Q; and in the heavy chain variable region, X_7 = M; X_8 = A; X_9 = D; X_{10} = T; X_{11} = V; X_{12} = R; and X_{13} = G.   In another embodiment, the variable light and heavy chain regions have

35   the amino acid sequence depicted in Figures 8A and 8B.

In another aspect, the invention provides purified nucleic acid segments encoding a light or heavy chain variable region of one of the monoclonal antibodies discussed above.

The invention also provides stable cell lines capable of producing the antibodies described above. The stable cell lines comprise nucleic acid segments respectively encoding the heavy chain and light chain of an antibody
5   described above. The segments are operably linked to first and second promoters to allow expression of the heavy and light chains.

The invention further provides pharmaceutical compositions comprising the antibodies described above and
10   methods of treatment using the same. The methods of treatment are particularly effective for inflammatory diseases including conditions such as ischemia-reperfusion injury, adult respiratory distress syndrome, sepsis, psoriasis and autoimmune disease.

15   In another aspect, the invention provides methods of generating an antibody capable of blocking E-selectin and/or P-selectin mediated functions. The method comprises concurrently or consecutively immunizing a mammal with P-selectin and E-selectin. B-cells from the mammal are
20   immortalized to generate immortalized cells producing antibodies. An immortalized cell is selected producing an antibody that specifically binds to E-selectin and to P-selectin.

The invention further provides methods of detecting
25   E-selectin and P-selectin bearing cells in a biological sample suspected of containing the cells. The method comprises contacting the sample with an antibody as described above to form an immune complex with the E-selectin and/or P-selectin bearing cells. The presence of the immune complex is then
30   detected to indicate the presence of the cells.

BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A and 1B: Crossreacting antibody 5C7.29
35   binds to naturally occurring human E-selectin. (a) Binding of known anti-E-selectin antibody H18/7 to activated (black histograms) and resting (grey histograms) HUVEC cells. (b) Binding of crossreacting antibody 5C7.29 to activated and

resting HUVEC cells. FACS fluorescence intensity is indicated by the X axis.

Figures 2A and 2B: Crossreacting antibody 5C7.29 binds to naturally occurring P-selectin. (a) Binding of known anti-P-selectin antibody WAPS 12.2 to platelets detected by staining with secondary antibody (black histogram), compared with staining with secondary antibody alone (control, grey histogram). (b) Binding of 5C7.29 to platelets, shown similarly.

Figure 3: Crossreactivity of 5C7.29 resides in a single monoclonal antibody. 5C7.29 antibody was incubated with excess of (a, c) parent L1-2 cells or (b, d) L1-2$^{P-selectin}$ transfectants, and resulting supernatants tested for reactivity with fresh samples of L1-2$^{P-selectin}$ (a, b) or L1-2$^{E-selectin}$ cells (c, d) by FACS analysis. This figure shows that L1-2$^{P-selectin}$ depletes reactivity for E-selectin.

Figure 4: Monoclonal antibody 5C7.29 blocks binding of HL-60 (neutrophil-like) cells to TNF-α-activated HUVEC cells (expressing E-selectin). Average of four experiments.

Figure 5. Monoclonal antibody 5C7.29 blocks binding of HL-60 cells to E-selectin transfectant cells. Average of four experiments.

Figure 6. Monoclonal antibodies 5C7.29, 2C9.11 and 1D8.10 block binding of platelets to HL-60 cells as shown by platelet rosetting. The chart shows the percentage of HL-60 cells with > 2 platelets bound (rosetted). Average of three experiments.

Figures 7A-7B. Sequences of the cDNA (light chain -- SEQ ID NO:1; heavy chain -- SEQ ID NO:3) and translated amino acid sequences (light chain -- SEQ ID NO:2; heavy chain -- SEQ ID NO:4) of the light chain (A) and heavy chain (B) variable regions of the mouse 5C7.29 antibody. The first amino acid of each mature chain is indicated by a double underline. The three CDRs in each chain are underlined.

Figures 8A-8B. Sequences of the synthetic DNA (light chain -- SEQ ID NO:5; heavy chain -- SEQ ID NO:7) and translated amino acid sequences (light chain -- SEQ ID NO:6; heavy chain -- SEQ ID NO:8) of the light chain (A) and heavy

9

chain (B) variable regions of the humanized 5C7.29 antibody. The first amino acid of each mature chain is indicated by a double underline. The three CDRs in each chain are underlined.

5   Figure 9. Schematic diagram of construction of humanized 5C7.29 antibody variable region genes.

         Figure 10. Humanized 5C7.29 antibody reactivity with E-selectin, P-selectin and L-selectin transfectants. L1-2 transfectant cell lines expressing the indicated selectin

10 were analyzed for reactivity with humanized 5C7.29 by flow cytometry.

         Figures 11A and 11B. Competitive binding of mouse and humanized 5C7.29 antibodies to cells expressing E-selectin (A) or P-selectin (B). Increasing concentrations of cold

15 competitor antibody were incubated with the cells in the presence of radiolabeled tracer mouse 5C7.29 antibody, and the ratio of bound/free radioactivity was determined.

         Figure 12. Inhibition of HL-60 cell adhesion to $CHO^{E\text{-selectin}}$ cells by mouse and humanized 5C7.29 antibodies.

20 Fluorescently labelled HL-60 cells were incubated with $CHO^{E\text{-selectin}}$ cells in the presence of the antibodies at the indicated concentrations. After washing, adherent cells were counted microscopically. The results from a representative experiment performed with each sample in quadruplicate (+/-

25 standard deviation) are shown.

         Figure 13. Inhibition of platelet rosetting to HL-60 cells by mouse and humanized 5C7.29 antibodies. Normal human platelets were incubated with HL-60 cells in the presence of the antibodies at the indicated concentrations.

30 After fixation, the percent of HL-60 cells with greater than 2 platelets bound (rosetted) was determined. The results shown are from a representative experiment performed with each sample in triplicate (+/-standard deviation).

35   DEFINITIONS

         The term "substantial identity" or "substantial homology" means that two peptide sequences, when optimally aligned, such as by the programs GAP or BESTFIT using default

gap weights, share at least 80 percent sequence identity,
preferably 90 percent sequence identity, more preferably at
least 95 percent sequence identity or more (*e.g.*, 99 percent
sequence identity). Preferably, residue positions which are
5   not identical differ by conservative amino acid substitutions.

The term "substantially pure" or "isolated" means an
object species is the predominant species present (*i.e.*, on a
molar basis it is more abundant than any other individual
species in the composition), and preferably a substantially
10 purified fraction is a composition wherein the object species
comprises at least about 50 percent (on a molar basis) of all
macromolecular species present. Generally, a substantially
pure composition will comprise more than about 80 to 90
percent by weight of all macromolecular species present in the
15 composition. Most preferably, the object species is purified
to essential homogeneity (contaminant species cannot be
detected in the composition by conventional detection methods)
wherein the composition consists essentially of a single
macromolecular species.

20   "Immunoglobulin," "antibody" or "antibody
peptide(s)" refers to an intact antibody, or a binding
fragment thereof that competes with the intact antibody for
specific binding. Binding fragments are produced by
recombinant DNA techniques, or by enzymatic or chemical
25 cleavage of intact immunoglobulins. Binding fragments include
Fab, Fab', F(ab')$_2$, Fv and single-chain antibodies. An
antibody other than a "bispecific" or "bifunctional" antibody
is understood to have each of its binding sites identical.

An antibody substantially inhibits adhesion of a
30 receptor to a counterreceptor when an excess of antibody
reduces the quantity of receptor bound to counterreceptor by
at least about 20%, 40%, 60% or 80%, and more usually greater
than about 85% (as measured in an *in vitro* competitive binding
assay).

35   The term epitope includes any protein determinant
capable of specific binding to an immunoglobulin or T-cell
receptor. Epitopic determinants usually consist of chemically
active surface groupings of molecules such as amino acids or

sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics.

An antibody is said to specifically bind an antigen
5   when the dissociation constant is ≤ 1 μM, preferably ≤ 100 nM and most preferably ≤ 10 nM.

The term patient includes human and veterinary subjects.

The term P-selectin counterreceptor denotes a
10   protein other than an antibody that specifically binds to P-selectin at least in part by noncovalent bonds. Specific binding maintains cells respectively bearing receptor and counterreceptor in physical proximity and may also transduce a change in physical or functional phenotype in either of the
15   cells or both. Other selectin counterreceptors are analogously defined.

DESCRIPTION OF THE PREFERRED EMBODIMENT

I.   Antibodies of the Invention

20   The invention provides antibodies that crossreact, *i.e.*, specifically bind, with E-selectin and P-selectin. Preferred antibodies block the functions of both of these molecules.

25   **A.   General Characteristics of Antibodies**

The basic antibody structural unit is known to comprise a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about 25 kDa) and one "heavy" chain (about 50-70
30   kDa). The amino-terminal portion of each chain includes a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The carboxy-terminal portion of each chain defines a constant region primarily responsible for effector function.
35   Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, and define the antibody's isotype as IgG, IgM, IgA, IgD and IgE, respectively. Within light and heavy

chains, the variable and constant regions are joined by a "J" region of about 12 or more amino acids, with the heavy chain also including a "D" region of about 10 more amino acids. (*See generally, Fundamental Immunology* (Paul, W., ed., 2nd ed.

5 Raven Press, N.Y., 1989), Ch. 7 (incorporated by reference in its entirety for all purposes).

The variable regions of each light/heavy chain pair form the antibody binding site. Thus, an intact antibody has two binding sites. Except in bifunctional or bispecific

10 antibodies, the two binding sites are the same. The chains all exhibit the same general structure of relatively conserved framework regions (FR) joined by three hypervariable regions, also called complementarity determining regions or CDRs. The CDRs from the two chains of each pair are aligned by the

15 framework regions, enabling binding to a specific epitope. From N-terminal to C-terminal, both light and heavy chains comprise the domains FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4. The assignment of amino acids to each domain is in accordance with the definitions of Kabat, *Sequences of Proteins of*

20 *Immunological Interest* (National Institutes of Health, Bethesda, MD, 1987 and 1991), or Chothia & Lesk, *J. Mol. Biol.* 196:901-917 (1987); Chothia et al., *Nature* 342:878-883 (1989).

A bispecific or bifunctional antibody is an artificial hybrid antibody having two different heavy/light

25 chain pairs and two different binding sites. Bispecific antibodies can be produced by a variety of methods including fusion of hybridomas or linking of Fab' fragments. *See, e.g.,* Songsivilai & Lachmann, *Clin. Exp. Immunol.* 79:315-321 (1990); Kostelny et al., *J. Immunol.* 148, 1547-1553 (1992).

30 Production of bispecific antibodies can be a relatively labor intensive process compared with production of conventional antibodies and yields and degree of purity are generally lower for bispecific antibodies. Bispecific antibodies do not exist in the form of fragments having a single binding site (*e.g.,*

35 Fab, Fab' and Fv).

13

B. Binding Specificity and Affinity

The immunoglobulins (or antibodies) of the invention exhibit specific binding to both P-selectin and E-selectin. That is, a single binding site on an antibody has affinity for
5   both P-selectin and E-selectin.   Thus, the antibodies bind to epitopes that are common to both molecules.   The antibodies bind to the natural and/or recombinant human forms for P-selectin and E-selectin (see Johnston et al., 1989, supra; Bevilacqua et al., 1989, supra).   Some antibodies may also
10.   bind P-selectin and/or E-selectin from nonhuman species.   Some of the antibodies also specifically bind to L-selectin (preferably human L-selectin (see Tedder, EPA 386,906 (1990)) whereas other antibodies of the invention do not. Surprisingly, the common epitopes bound by the crossreacting
15   antibodies of the invention are also epitopes important for both E-selectin and P-selectin to interact with their counterreceptors on activated leukocytes, such as neutrophils. Thus, most crossreacting antibodies of the invention block the functional interactions of E-selectin or P-selectin and
20   usually those of both of these molecules.   Some crossreacting antibodies also block the functional interactions of L-selectin whereas others do not.

Blockage of P-selectin-mediated functions can be demonstrated in vitro.   In vitro assays measure the capacity
25   of an antibody to inhibit binding of P-selectin to a counterreceptor.   Suitable sources of P-selectin for such assays are purified P-selectin (or an extracellular domain thereof), cells transfected with P-selectin, activated endothelial cells or platelets.   Suitable sources of
30   counterreceptor are leukocytes, neutrophils, monocytes, or HL-60 cells (ATCC CCL 240) and appropriate cell lines transfected with L-selectin.   Neutrophils can be isolated from whole blood (preferably human blood) by Ficoll-Hypaque gradient centrifugation.   Neutrophils are usually pretreated
35   with rabbit serum to block Fc receptors before adding to a binding assay.   When both components in the binding assay are cellular, binding can be assayed microscopically or by flow cytometry.   See Kishimoto et al., supra.   When one or both

components is a purified protein, one component is usually immobilized to a solid phase and the other labelled. Binding is then assayed from label bound to the solid phase. Usually, the antibody is preincubated with the source of P-selectin

5   before adding the source of counterreceptor to the incubation mixture. Blocking activity is shown when an excess of antibody, *i.e.*, 5-fold, 10-fold or up to 100-fold, substantially inhibits binding of P-selectin to its counterreceptor. The precise degree of inhibition will depend

10   on the assay used. In an assay that measures inhibition of platelet binding to HL-60 cells, an excess of P-selectin blocking antibodies typically exhibits at least 50, 60, 70, 80 or 90% and usually about 80-90% inhibition.

The binding specificity of many blocking antibodies

15   of the invention is further defined by their capacity to bind P-selectin in the complete or substantial absence of Ca^{++} (*e.g.*, in the presence of 2 mM EDTA (a calcium chelator) and the absence of Ca^{++} in an *in vitro* assay). By contrast, most blocking antibodies against P-selectin isolated to date

20   require Ca^{++} for activity. *See* Geng et al., *J. Biol. Chem.* 266:22313-22318 (1991). Antibodies requiring a Ca^{++} cofactor for blocking activity may be less effective in *in vivo* conditions where levels of Ca^{++} are expected to fluctuate.

The capacity of the antibodies of the invention to

25   block E-selectin-mediated functions can be demonstrated by analogous *in vitro* assays to those employed to show blocking of P-selectin mediated functions. Suitable sources of E-selectin are mammalian cell lines transfected with E-selectin, activated endothelial cells, as well as purified

30   E-selectin (or extracellular domains thereof). If the assay is performed using purified E-selectin, the E-selectin can be immobilized to a solid support. Suitable sources of counterreceptors to E-selectin are leukocytes, neutrophils, monocytes, and HL-60 cells and appropriate cell lines

35   transfected with L-selectin. The degree of binding inhibition will again depend on the components in the assay. In an assay that measures binding between activated endothelial cells and HL-60 cells, the antibodies of the invention, when present in

excess, typically exhibit at least about 20, 40, 60, 80% inhibition or more typically about 25-75% or 50% inhibition.

The capacity of antibodies to block L-selectin mediated functions can be demonstrated in a variety of *in*

5   *vitro* assays. *See, e.g.*, copending applications 08/160,516, filed November 30, 1993 and 08/160,074, filed November 30, 1993 (incorporated by reference in their entirety for all purposes). A simple visual assay for detecting such interaction has been described by Kishimoto et al., *supra*.

10 Briefly, monolayers of human umbilical vein cells are stimulated with IL-1. Neutrophils, with or without pretreatment with the antibody under test, are added to the monolayer under defined conditions, and the number of adhering neutrophils is determined microscopically. In one method, the

15 neutrophils are obtained from human leukocyte adhesion deficient patients. *See* Anderson et al., *Ann. Rev. Med.* 38:175 (1987). The neutrophils from such patients lack integrin receptors, whose binding to neutrophils might obscure the effects of blocking L-selectin binding.

20   Preferred antibodies selectively bind a functional epitope on P-selectin and E-selectin molecules associated with a response to tissue injury and inflammation. Binding of the antibodies to a functional epitope on P-selectin and E-selectin effectively inhibits adhesion of leukocytes to the

25 activated vascular endothelium and/or to activated platelets *in vivo*. Preferred antibodies impair the adhesion of leukocytes to the activated vascular endothelium to prevent or inhibit an inflammatory and/or thrombotic condition.

In vivo blocking efficacy can be demonstrated in the

30 same animal models that have been used to show efficacy for antibodies specific for a single adhesion molecule. For example, Mulligan et al., 1991, 1992, *supra*, describe rat models to test the efficacy of antibodies in protecting against lung injury; Coughlan et al., 1994, describe a rat

35 model for testing the efficacy of antibodies in treatment of systemic endotoxemia; and Weyrich et al., *supra*, describe a cat model for testing the protective effect of antibodies in myocardial ischemia and reperfusion injury. Other animal

models for various inflammatory diseases and disorders are described by Arfors et al., *Blood* 69:338 (1987) (skin lesions); Tuomanen et al., *J. Exp. Med.* 170:959 (1989) (brain edema and death produced by bacterial meningitis); Lindbom et

5 al., *Clin. Immunol. Immunopath.* 57:105 (1990) (tissue edema associated with delayed-type hypersensitivity reactions); Wegner et al., *Science* 247:456 (1990) (airway hyperresponsiveness in allergic asthma); Goldman et al., *FASEB J.* 5:A509 (1991) (remote lung injury following aspiration);

10 Gundel et al., *J. Clin. Invest.* 88:1407 (1991) (late-phase bronchoconstriction following antigen challenge); Hutchings et al., *Nature* 346:639 (1990) (diabetes); Flavin et al., *Transplant, Proc.* 23:533 (1991) (cardiac allograft survival); Wegner et al., *Am. Rev. Respir. Dis.* 143:A544 (1991) (lung

15 damage and dysfunction secondary to oxygen toxicity); Cosimi et al., *J. Immunol.* 144:4604 (1990) (renal allograft rejection); Jasin et al., *Arthritis Rheum.* 33:S34 (1990) (antigen-induced arthritis); Thomas et al., *FASEB J.* 5:A509 (1991) (vascular injury and death in endotoxic shock); Bucky

20 et al., *Proc. Am. Burn Assoc.* 23:133 (1991) (burns); Hernandez et al., *Am. J. Physiol.* 253:H699 (1987) (permeability edema following ischemia reperfusion (IR) of intestine); Winquist et al., *Circulation* 82:III (1990); Ma et al., *Cir. Res.* 82:III (1990) (myocardial damage following myocardial infarction);

25 Mileski et al., *Surgery* 108:206 (1990) (vascular and tissue damage following hemorrhagic shock and resuscitation); Clark et al., *Stroke* 22:877 (1991) (central nervous system damage following I/R of the spinal cord); Mileski et al., *Proc. Am. Burn Assoc.* 22:164 (1990) (edema and tissue damage following

30 frostbite and rewarming); Simpson et al., *Circulation* 81:226 (1990) (infarct size following I/R of myocardium). Preferred antibodies show efficacy in at least one and usually several of these inflammatory and thrombotic diseases and conditions.

Many of the blocking antibodies of the invention

35 show the same or similar binding specificity as one of the exemplary antibodies designated 5C7.29, 2C9.11 and 1D8.10. That is, the antibodies compete with at least one of the exemplified antibodies for specific binding to E-selectin

and/or P-selectin. The E-selectin and P-selectin used in the test is preferably human, and may be natural or recombinant. Competition between antibodies is determined by an assay in which the immunoglobulin under test inhibits specific binding

5 of a reference antibody (*e.g.*, 5C7.29) to an antigenic determinant on a P-selectin and/or E-selectin molecule. Numerous types of competitive binding assays are known, for example: solid phase direct or indirect radioimmunoassay (RIA), solid phase direct or indirect enzyme immunoassay

10 (EIA), sandwich competition assay (*see* Stahli et al., *Methods in Enzymology* 9:242-253 (1983)); solid phase direct biotin-avidin EIA (*see* Kirkland et al., *J. Immunol.* 137:3614-3619 (1986)); solid phase direct labeled assay, solid phase direct labeled sandwich assay (*see* Harlow and Lane, "Antibodies, A

15 Laboratory Manual," Cold Spring Harbor Press (1988)); solid phase direct label RIA using I-125 label (*see* Morel et al., *Molec. Immunol.* 25(1):7-15 (1988)); solid phase direct biotin-avidin EIA (Cheung et al., *Virology* 176:546-552 (1990)); and direct labeled RIA (Moldenhauer et al., *Scand. J. Immunol.*

20 32:77-82 (1990)). Typically, such an assay involves the use of purified P-selectin or E-selectin bound to a solid surface or cells bearing either of these, an unlabelled test immunoglobulin and a labelled reference immunoglobulin. Competitive inhibition is measured by determining the amount

25 of label bound to the solid surface or cells in the presence of the test immunoglobulin. Usually the test immunoglobulin is present in excess. Antibodies identified by competition assay (competing antibodies) include antibodies binding to the same epitope as the reference antibody and antibodies binding

30 to an adjacent epitope sufficiently proximal to the epitope bound by the reference antibody for steric hindrance to occur. Usually, when a competing antibody is present in excess, it will inhibit specific binding of a reference antibody to P-selectin and/or E-selectin by at least 50 or 75%.

35 The antibodies of the invention usually exhibit a specific binding affinity for P-selectin and E-selectin of greater than or equal to about 10^6, 10^7, 10^8, 10^9, or 10^{10} M^{-1}. However, antibodies do not necessarily show the same specific

binding affinity for each of these ligands. Usually the upper
limit of binding affinity of the antibodies is within a factor
of about three, five or ten of that of one of the exemplified
antibodies. Often the lower limit of binding affinity is also

5   within a factor of about three, five or ten of that of the
exemplified antibodies. The term "about" encompasses the
degree of experimental error that may typically occur in the
measurement of binding affinities.

A hybridoma producing the 5C7.29 antibody has been

10   deposited with the American Type Culture Collection, 12301
Parklawn Dr., Rockville, Maryland under the Budapest Treaty on
May 25, 1994 and given the Accession No. ATCC CRL 11640. The
production of this antibody is described in Example 1.

15   C.   Production of Antibodies
(1)   Nonhuman Antibodies
Mouse, or other nonhuman antibodies crossreactive
with P-selectin and E-selectin can be obtained using a variety
of immunization strategies. In some strategies, nonhuman

20   animals (usually nonhuman mammals), such as mice, are
immunized with E-selectin and P-selectin antigens, either
concurrently or consecutively. In other strategies, nonhuman
animals are immunized with only one of these antigens.
Preferred immunogens are cells stably transfected with

25   P-selectin or E-selectin and expressing these molecules on
their cell surface. Other preferred immunogens include
P-selectin and E-selectin proteins or epitopic fragments of
P-selectin and E-selectin containing the segments of these
molecules that bind to the exemplified crossreacting

30   antibodies.
Mouse or non-human antibodies crossreactive with all
three selectins, i.e., P-selectin, E-selectin, and L-selectin,
can be generated by similar strategies. Briefly, mice are
immunized either simultaneously or sequentially with cells

35   stably transfected with either P-selectin, E-selectin, or
L-selectin, or purified selectin proteins or epitopic
fragments thereof.

Antibody-producing cells obtained from the immunized animals are immortalized and selected for the production of an antibody which specifically binds to multiple selectins. *See generally*, Harlow & Lane, *Antibodies, A Laboratory Manual*

5 (C.S.H.P. NY, 1988) (incorporated by reference for all purposes). The binding assays for the different selectins can be performed separately or concurrently. Concurrent analysis is conveniently performed by two-color FACS screening after incubation of hybridoma supernatants to cells transfected with

10 selectins. For example, two populations of cells respectively expressing E-selectin and P-selectin are differentially labelled with a first label and tested for capacity to bind hybridomas supernatants. Binding is detected using an appropriate secondary antibody bearing a second label. This

15 scheme is readily extendible to allow simultaneous detection of binding to all three selectins by differentially labelling three populations of cells respectively expressing E-selectin, P-selectin and L-selectin with different intensities of the first label. Alternatively, separate screening for

20 E-selectin, P-selectin and, if desired, L-selectin binding, can be achieved by single color FACS analysis of supernatant binding to transfectant cells or by binding assay to immobilized E-selectin, P-selectin, or L-selectin. Crossreacting antibodies are then further screened for their

25 capacity to block functional properties of E-selectin, P-selectin and L-selectin using the *in vitro* and *in vivo* assays described above. Most antibodies that crossreact with P-selectin or E-selectin also block the functional capacity of both of these molecules to interact with a counterreceptor.

30

(2) Humanized Antibodies

The invention provides humanized antibodies having similar binding specificity and affinity to selected mouse or other nonhuman antibodies. Humanized antibodies are formed by

35 linking CDR regions (preferably CDR1, CDR2 and CDR3) of non-human antibodies to human framework and constant regions by recombinant DNA techniques. *See* Queen et al., *Proc. Natl. Acad. Sci. USA* 86:10029-10033 (1989) and WO 90/07861

20

(incorporated by reference in their entirety for all
purposes). The humanized immunoglobulins have variable region
framework residues substantially from a human immunoglobulin
(termed an acceptor immunoglobulin) and complementarity
5   determining regions substantially from a mouse immunoglobulin
described above, *e.g.*, the 5C7.29 antibody (referred to as the
donor immunoglobulin). The constant region(s), if present,
are also substantially from a human immunoglobulin.

In principal, a framework sequence from any human
10   antibody may serve as the template for CDR grafting. However,
it has been demonstrated that straight CDR replacement onto
such a framework often leads to significant loss of binding
affinity to the antigen (Glaser et al., J. Immunol. 149: 2606
(1992); Tempest et al., Biotechnology 9: 266 (1992); Shalaby
15   et al., J. Exp. Med. 17: 217 (1992)). The more homologous a
human antibody is to the original murine antibody, the less
likely will combining the murine CDRs with the human framework
be to introduce distortions into the CDRs that could reduce
affinity.   Therefore, homology (that is, percent sequence
20   identity) of at least 65% between the humanized antibody
variable region framework and the donor antibody variable
region framework is preferred.

The heavy and light chain variable region framework
residues can be derived from the same or different human
25   antibody sequences. However, a heavy chain and light chain
framework sequences chosen from the same human antibody reduce
the possibility of incompatibility in assembly of the two
chains. The human antibody sequences can be the sequences of
naturally occurring human antibodies or can be consensus
30   sequences of several human antibodies. *See* Carter et al.,
WO 92/22653. Certain amino acids from the human variable
region framework residues can be selected for substitution
based on their possible influence on CDR conformation and/or
binding to antigen. Investigation of such possible influences
35   is by modeling, examination of the characteristics of the
amino acids at particular locations, or empirical observation
of the effects of substitution or mutagenesis of particular
amino acids.

For example, when an amino acid differs between a murine 5C7.29 variable region framework residue and a selected human variable region framework residue, the human framework amino acid should usually be substituted by the equivalent

5   framework amino acid from the mouse antibody when it is reasonably expected that the amino acid:

(1)   contacts antigen directly,

(2)   is adjacent to a CDR region in the sequence, or

(3)   otherwise interacts with a CDR region (*e.g.*, is

10   within about 4-6 Å of a CDR region).

Other candidates for substitution are acceptor human framework amino acids that are unusual for a human immunoglobulin at that position. These amino acids can be substituted with amino acids from the equivalent position of

15   the donor antibody or from the equivalent positions of more typical human immunoglobulins. The variable region frameworks of humanized immunoglobulins usually show at least 85% sequence identity to a human variable region framework sequence or consensus of such sequences.

20

(3) Human Antibodies

In another aspect of the invention, human antibodies cross-reactive with E-selectin and P-selectin are provided. These antibodies are produced by a variety of techniques

25   described below. Some human antibodies are selected by competitive binding experiments, or otherwise, to have the same epitope specificity as an exemplified mouse antibody, such as 5C7.29. Such antibodies are particularly likely to share similar therapeutic properties.

30

a. Trioma Methodology

The basic approach and an exemplary cell fusion partner, SPAZ-4, for use in this approach have been described by Oestberg et al., *Hybridoma* 2:361-367 (1983); Oestberg, U.S.

35   Patent No. 4,634,664; and Engleman et al., US Patent 4,634,666 (each of which is incorporated by reference in its entirety for all purposes). The antibody-producing cell lines obtained by this method are called triomas, because they are descended

22

from three cells--two human and one mouse. Initially, a mouse
myeloma line is fused with a human B-lymphocyte to obtain a
non-antibody-producing xenogeneic hybrid cell, such as the
SPAZ-4 cell line described by Oestberg, *supra*. The xenogeneic
5   cell is then fused with an immunized human B-lymphocyte to
obtain an antibody-producing trioma cell line. Triomas have
been found to produce antibody more stably than ordinary
hybridomas made from human cells.

         The B-lymphocytes are obtained from the blood,
10   spleen, lymph nodes or bone marrow of a human donor. *In vivo*
immunization of a living human with E-selectin and/or
P-selectin is usually undesirable because of the risk of
initiating a harmful response. Thus, B-lymphocytes are
usually immunized *in vitro* with an E-selectin and/or
15   P-selectin or an antigenic fragment of either of these, or a
cell bearing either of these. Specific epitopic fragments
consisting essentially of the amino acid segments that bind to
one of the exemplified murine antibodies are preferred for *in
vitro* immunization. B-lymphocytes are typically exposed to
20   antigen for a period of 7-14 days in a media such as RPMI-1640
(*see* Engleman, *supra*) supplemented with 10% human serum.

         The immunized B-lymphocytes are fused to a
xenogeneic hybrid cell such as SPAZ-4 by well known methods.
For example, the cells are treated with 40-50% polyethylene
25   glycol of MW 1000-4000, at about 37 degrees, for about 5-10
min. Cells are separated from the fusion mixture and
propagated in media selective for the desired hybrids (*e.g.*,
HAT or AH). Clones secreting antibodies having the required
binding specificity are identified by assaying the trioma
30   culture medium for the ability to bind to E-selectin and
P-selectin using the same methods as discussed above for
nonhuman antibodies. Triomas producing human antibodies
having the desired specificity are subcloned by, *e.g.*, the
limiting dilution technique and grown *in vitro* in culture
35   medium.

         Although triomas are genetically stable they may not
produce antibodies at very high levels. Expression levels can
be increased by cloning antibody genes from the trioma into

23

one or more expression vectors, and transforming the vector
into a cell line such as the cell lines discussed, *infra*, for
expression of recombinant or humanized immunoglobulins.

5   b.   Transgenic Non-Human Mammals
                    Human antibodies crossreactive with P-selectin
and E-selectin can also be produced from non-human transgenic
mammals having transgenes encoding at least a segment of the
human immunoglobulin locus. Usually, the endogenous
10   immunoglobulin locus of such transgenic mammals is
functionally inactivated. Preferably, the segment of the
human immunoglobulin locus includes unrearranged sequences of
heavy and light chain components. Both inactivation of
endogenous immunoglobulin genes and introduction of exogenous
15   immunoglobulin genes can be achieved by targeted homologous
recombination, or by introduction of YAC chromosomes. The
transgenic mammals resulting from this process are capable of
functionally rearranging the immunoglobulin component
sequences, and expressing a repertoire of antibodies of
20   various isotypes encoded by human immunoglobulin genes,
without expressing endogenous immunoglobulin genes. The
production and properties of mammals having these properties
are described in detail by, *e.g.*, Lonberg et al., WO93/12227
(1993); Kucherlapati, WO 91/10741 (1991) (each of which is
25   incorporated by reference in its entirety for all purposes).
Transgenic mice are particularly suitable. Crossreacting
P-selectin/E-selectin human antibodies are obtained by
immunizing a transgenic nonhuman mammal, such as described by
Lonberg or Kucherlapati, *supra*, according to the same strategy
30   as discussed for a nontransgenic nonhuman animal (section
I.C.(1)). Monoclonal antibodies are prepared by, *e.g.*, fusing
B-cells from such mammals to suitable myeloma cell lines using
conventional Kohler-Milstein technology.

35   c.   Phage Display Methods
                    A further approach for obtaining human
crossreacting antibodies to E-selectin and P-selectin is to
screen a DNA library from human B cells as described by Dower

et al., WO 91/17271 and McCafferty et al., WO 92/01047 (each
of which is incorporated by reference in its entirety for all
purposes). In these methods, libraries of phage are produced
in which members display different antibodies on their outer
5   surfaces. Antibodies are usually displayed as Fv or Fab
fragments. Phage displaying antibodies are selected by
affinity enrichment for binding to either P-selectin or
E-selectin. Phage identified by the initial screen are then
further screened for crossreaction with the other ligand.

10   In a variation of the phage-display method, human
antibodies having the binding specificity of a selected murine
antibody can be produced. *See* Winter, WO 92/20791. In this
method, either the heavy or light chain variable region of the
selected murine antibody (*e.g.*, 5C7.29) is used as a starting
15   material. If, for example, a light chain variable region is
selected as the starting material, a phage library is
constructed in which members displays the same light chain
variable region (*i.e.*, the murine starting material) and a
different heavy chain variable region. The heavy chain
20   variable regions are obtained from a library of rearranged
human heavy chain variable regions. A phage showing strong
specific binding for P-selectin and E-selectin (*e.g.*, at least
10^8 and preferably at least 10^9 M^{-1}) is selected. The human
heavy chain variable region from this phage then serves as a
25   starting material for constructing a further phage library.
In this library, each phage displays the same heavy chain
variable region (*i.e.*, the region identified from the first
display library) and a different light chain variable region.
The light chain variable regions are obtained from a library
30   of rearranged human variable light chain regions. Again,
phage showing strong specific binding for P-selectin and
E-selectin are selected. These phage display the variable
regions of completely human antibodies that crossreact with
E-selectin and P-selectin. These antibodies usually have the
35   same or similar epitope specificity as the murine starting
material (*e.g.*, 5C7.29).

D.   Bispecific Antibodies

The invention also provides bispecific or bifunctional antibodies that have one binding site that specifically binds to P-selectin and E-selectin and a second
5   binding site that specifically binds to a second moiety. In bispecific antibodies, one heavy and light chain pair is usually from a crossreacting antibody and the other pair from an antibody raised against another epitope. This results in the property of multi-functional valency, i.e., ability to
10   bind at least two different epitopes simultaneously, one of which is the epitope to which the anti P-selectin/E-selectin crossreacting antibody binds. The other epitope could be e.g., an epitope on L-selectin.

E.   Other Therapeutic Agents

15   Having produced an antibody having desirable properties, such as 5C7.29 and the other exemplified antibodies, other nonantibody agents having similar binding specificity/and or affinity can be produced by a variety of methods. For example, Fodor et al., US 5,143,854, discuss a
20   technique termed VLSIPS™, in which a diverse collection of short peptides are formed at selected positions on a solid substrate. Such peptides could then be screened for binding to an epitopic fragment recognized by 5C7.29, optionally in competition with the 5C7.29. Libraries of short peptides can
25   also be produced using phage-display technology, *see, e.g.*, Devlin WO91/18980. The libraries can be screened for binding to an epitopic fragment recognized by *e.g.*, 5C7.29, optionally in competition with 5C7.29.

II.   Nucleic Acids

30   The genes encoding the heavy and light chains of immunoglobulins produced by hybridoma or trioma cell lines secreting crossreacting antibodies are cloned according to methods described in Sambrook et al., *Molecular Cloning: A*
35   *Laboratory Manual*, 2nd ed. (Cold Spring Harbor, NY, 1989); Berger & Kimmel, Methods in Enzymology, Volume 152, *Guide to Molecular Cloning Techniques* (Academic Press, Inc., San Diego, CA, 1987); Co et al., *J. Immunol.* 148:1149 (1992). For

26

example, genes encoding heavy and light chains are cloned from
a hybridoma's genomic DNA or cDNA produced by reverse
transcription of RNA. Cloning is accomplished by conventional
techniques including the use of PCR primers that hybridize to
5   the sequences flanking or overlapping the genes, or segments
of genes, to be cloned.

        Typically, recombinant constructs comprise DNA
segments encoding a complete human immunoglobulin heavy chain
and/or a complete human immunoglobulin light chain of an
10 immunoglobulin expressed by a hybridoma or trioma cell line.
Alternatively, DNA segments encoding only a portion of the
primary antibody genes are produced, which portions possess
binding and/or effector activities. Other recombinant
constructs contain segments of immunoglobulin genes fused to
15 segments of other immunoglobulin genes, particularly segments
of other human constant region sequences (heavy and/or light
chain). Human constant region sequences can be selected from
various reference sources, including those listed in Kabat et
al., *supra*.

20   DNA segments encoding crossreacting P-selectin/
E-selectin antibodies can be modified by recombinant DNA
techniques such as site-directed mutagenesis (*see* Gillman &
Smith, *Gene* 8:81-97 (1979); Roberts et al., *Nature*, 328:731-
734 (1987). Such modified segments will usually retain
25 antigen binding capacity and/or effector function. Moreover,
the modified segments are usually not so far changed from the
original sequences to prevent hybridization to these sequences
under stringent conditions. The modified segments will
usually encode an immunoglobulin showing substantial sequence
30 identity to a reference immunoglobulin from which it was
derived. Because, like many genes, immunoglobulin genes
contain separate functional regions, each having one or more
distinct biological activities, the genes may be fused to
functional regions from other genes to produce fusion proteins
35 (*e.g.*, immunotoxins) having novel properties or novel
combinations of properties.

        The recombinant polynucleotide constructs will
typically include an expression control sequence operably

linked to the coding sequences, including naturally-associated
or heterologous promoter regions. Preferably, the expression
control sequences will be eukaryotic promoter systems in
vectors capable of transforming or transfecting eukaryotic

5   host cells. Once the vector has been incorporated into the
appropriate host, the host is maintained under conditions
suitable for high level expression of the nucleotide
sequences, and the collection and purification of the
crossreacting antibodies.

10   These expression vectors are typically replicable in
the host organisms either as episomes or as an integral part
of the host chromosomal DNA. Commonly, expression vectors
will contain selection markers, e.g., ampicillin-resistance or
hygromycin-resistance, to permit detection of those cells

15   transformed with the desired DNA sequences.

        E. coli is one prokaryotic host particularly useful
for cloning the DNA sequences of the present invention.
Microbes, such as yeast are also useful for expression.
Saccharomyces is a preferred yeast host, with suitable vectors

20   having expression control sequences, an origin of replication,
termination sequences and the like as desired. Typical
promoters include 3-phosphoglycerate kinase and other
glycolytic enzymes. Inducible yeast promoters include, among
others, promoters from alcohol dehydrogenase, isocytochrome C,

25   and enzymes responsible for maltose and galactose utilization.

        Mammalian cells are a preferred host for expressing
nucleotide segments encoding immunoglobulins or fragments
thereof. See Winnacker, From Genes to Clones, (VCH
Publishers, NY, 1987). A number of suitable host cell lines

30   capable of secreting intact heterologous proteins have been
developed in the art, and include CHO cell lines, various COS
cell lines, HeLa cells, L cells and myeloma cell lines.
Preferably, the cells are nonhuman. Expression vectors for
these cells can include expression control sequences, such as

35   an origin of replication, a promoter, an enhancer (Queen et
al., Immunol. Rev. 89:49 (1986)), and necessary processing
information sites, such as ribosome binding sites, RNA splice
sites, polyadenylation sites, and transcriptional terminator

28

sequences.   Preferred expression control sequences are
promoters derived from endogenous genes, cytomegalovirus,
SV40, adenovirus, bovine papillomavirus, and the like. *See* Co
et al., *J. Immunol.* 148:1149 (1992).

5   The vectors containing the DNA segments of interest
can be transferred into the host cell by well-known methods,
depending on the type of cellular host. For example, calcium
chloride transfection is commonly utilized for prokaryotic
cells, whereas calcium phosphate treatment, electroporation,

10   lipofection, biolistics or viral-based transfection may be
used for other cellular hosts. Other methods used to
transform mammalian cells include the use of polybrene,
protoplast fusion, liposomes, electroporation, and
microinjection (*see generally*, Sambrook et al., *supra*).

15   Once expressed, crossreacting immunoglobulins of the
invention can be purified according to standard procedures of
the art, including HPLC purification, column chromatography,
gel electrophoresis and the like (*see generally*, Scopes,
Protein Purification (Springer-Verlag, NY, 1982)).

20

III.   Epitope Mapping

               The P-selectin epitope(s) bound by the 5C7.29 or
other crossreacting antibody can be determined by providing a
family of fragments containing different amino acid segments

25   from P-selectin.   Each fragment typically comprises at least
4, 6, 8, 10, 20, 50 or 100 contiguous amino acids. The family
of polypeptide fragments cover much or all of the amino acid
sequence of the extracellular domain of a P-selectin
polypeptide. Members of the family are tested individually

30   for binding to *e.g.*, the 5C7.29 antibody. The smallest
fragment that can specifically bind to the antibody being
tested contains the amino acid sequence of the epitope
recognized by the antibody. The E-selectin epitope bound by
the antibody is mapped by an analogous strategy using a family

35   of peptides from E-selectin. The respective epitopes on
P-selectin and E-selectin are expected to map to segments of
these molecules showing a high degree of sequence identity.
The epitopic fragments are useful as immunogens for generating

further crossreacting antibodies. The epitopic fragments are also useful as therapeutic agents that agonize or antagonize the function of P-selectin or E-selectin.

Another method to map epitopes involves testing the 5 ability of an antibody to bind to E-selectin or P-selectin to which random mutations have been introduced. This method is described in more detail in Example 9.

IV.   Pharmaceutical Compositions

10 The pharmaceutical compositions for use in the therapeutic methods discussed *infra*, typically comprise an active agent, such as crossreacting E-selectin/P-selectin antibody, dissolved in an acceptable carrier, preferably an aqueous carrier. Some compositions contain a cocktail of 15 multiple active agents, for example, a crossreacting antibody and a thrombolytic agent. A variety of aqueous carriers can be used, *e.g.*, water, buffered water, phosphate buffered saline (PBS), 0.4% saline, 0.3% glycine, human albumin solution and the like. These solutions are sterile and 20 generally free of particulate matter. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, for example, sodium acetate, sodium chloride, 25 potassium chloride, calcium chloride and sodium lactate. The concentration of antibody in these formulations can vary widely, *i.e.*, from less than about 0.005%, usually at least about 1% to as much as 15 or 20% by weight and will be selected primarily based on fluid volumes, viscosities, and so 30 forth, in accordance with the particular mode of administration selected.

Thus, a typical pharmaceutical composition for injection could be made up to contain 1 ml sterile buffered water, and 1-10 mg of immunoglobulin. A typical composition 35 for intravenous infusion could be made up to contain 250 ml of sterile Ringer's solution, and 150 mg of antibody. Methods for preparing parenterally administrable compositions are described in *Remington's Pharmaceutical Science* (15th ed.,

30

Mack Publishing Company, Easton, PA, 1980), which is
incorporated by reference in its entirety for all purposes.

Therapeutic agents of the invention can be frozen or
lyophilized for storage and reconstituted in a suitable

5   carrier prior to use. Lyophilization and reconstitution can
lead to varying degrees of antibody activity loss (e.g., with
conventional immune globulins, IgM antibodies tend to have
greater activity loss than IgG antibodies). Dosages may have
to be adjusted to compensate.

10

V.   Therapeutic Methods

The antibodies of the present invention are useful
for treatment of inflammatory diseases and conditions,
especially those which are mediated by neutrophils. The dual

15   specificity of the antibodies leads to the inhibition of
inflammatory events mediated by either P-selectin or
E-selectin.

For example, the antibodies are suitable for
therapeutic and prophylactic treatment of ischemia-reperfusion

20   injury caused by myocardial infarction, cerebral ischemic
event (e.g., stroke), renal, hepatic or splenial infarction,
brain surgery, lung injury, shock, cardiac surgery (e.g.,
coronary artery bypass), elective angioplasty, and the like.
Other preferred applications are the treatment of sepsis,

25   adult respiratory distress syndrome, and multiple organ
failure. The antibodies are also useful for treating injury
due to trauma, burns, frostbite or damage to the spinal cord.
The antibodies will also find use in treating autoimmune
diseases including rheumatoid arthritis, systemic lupus

30   erythematosus, multiple sclerosis, type I diabetes and
uveitis, in treating inflammatory diseases of the skin such as
psoriasis, and in treating meningitis and encephalitis. The
antibodies are also useful for treating allergic rhinitis,
asthma and anaphylaxis. Other typical applications are the

35   prevention and treatment of organ transplant rejection and
graft-versus-host disease.

The pharmaceutical compositions containing the
antibodies are particularly useful for parenteral

administration, *i.e.*, subcutaneously, intramuscularly or intravenously. The antibodies of the invention may also be administered, typically for local application, by gavage or lavage, intraperitoneal injection, ophthalmic ointment,

5   topical ointment, intracranial injection (typically into a brain ventricle), intrapericardiac injection, or intrabursal injection.

The compositions containing the present antibodies or a cocktail thereof can be administered for prophylactic

10 and/or therapeutic treatments. In therapeutic applications, compositions are administered to a patient already suffering from an inflammatory disease, in an amount sufficient to cure or at least partially arrest the disease and its complications. An amount adequate to accomplish this is

15 defined as a "therapeutically effective dose." Amounts effective for this use will depend upon the severity of the disease and the general state of the patient's own immune system, but generally range from about 1 to about 200 mg of antibody per dose, with dosages of from 5 to 80 mg per patient

20 being more commonly used. Dosing schedules will vary with the disease state and status of the patient, and will typically range from a single bolus dosage or continuous infusion to multiple administrations per day (*e.g.*, every 4-6 hours), or as indicated by the treating physician and the patient's

25 condition. In life-threatening or potentially life-threatening situations, it is possible and may be felt desirable by the treating physician to administer substantial excesses of these antibodies.

In prophylactic applications, compositions

30 containing the present antibodies or a cocktail thereof are administered to a patient not already suffering from a particular disease to enhance the patient's resistance. Such an amount is defined to be a "prophylactically effective dose." In this use, the precise amounts again depend upon the

35 patient's state of health and general level of immunity, but generally range from 1 to 80 mg per dose. Preferred prophylactic uses are for the prevention of adult respiratory distress syndrome in patients already suffering from sepsis or

trauma; prevention of organ transplant rejection; and prevention of reperfusion injury in patients suffering from ischemia. In seriously ill patients, dosages of about 50 to 150 mg of humanized or human immunoglobulin per administration

5   are frequently used, and larger dosages may be indicated.

Single or multiple administrations of the compositions can be carried out with dose levels and pattern being selected by the treating physician. In any event, the pharmaceutical formulations should provide a quantity of the

10   antibody(ies) of this invention sufficient to treat the patient effectively.

The antibodies can also be used in combination with other antibodies, particularly antibodies reactive with different adhesion molecules. For example, suitable

15   antibodies include those specific for CD11a, CD11b, CD18, L-selectin, and ICAM-1. Other suitable antibodies are those specific for lymphokines, such as IL-1, IL-2 and IFN-γ, and their receptors. The antibodies of the invention can also be administered in conjunction with chemotherapeutic agents.

20   Suitable agents include non-steroidal anti-inflammatory drugs and corticosteroids, but numerous additional agents (e.g., cyclosporin) can also be used.

In some therapeutic methods of ischemia-reperfusion therapy, crossreacting antibodies are used in combination with

25   thrombolytic agents. In previous methods, patients with myocardial infarction or unstable angina are often treated by opening the occluded coronary artery. Reopening of the obstructed coronary artery can be achieved by administration of thrombolytic agents which lyse the clot causing the

30   obstruction, and which, thereby, restore coronary blood flow. Reperfusion of the vessel can also be achieved by percutaneous transluminal coronary angioplasty (PTCA) by means of balloon dilation of the obstructed and narrowed segment of the coronary artery. However, restoration of coronary blood flow

35   leads to ischemia-reperfusion injury in prior methods.

In the present methods, ischemia-reperfusion injury is reduced or prevented by combination of a thrombolytic agent or of PTCA with crossreacting E-selectin/P-selectin

antibodies.   Antibodies are usually administered
prophylactically before, or at the same time as,
administration of thrombolytic agents or initiation of PTCA.
Further doses of antibody are then often administered during
5   and after thrombolytic or angioplastic treatment.   The
interval between prophylactic administration of the antibodies
and initiation of thrombolytic or angioplastic treatment is
usually 5-60 mins, preferably 5-30 min, and most preferably
5-10 min.   The antibodies are administered parentally,
10   preferably by intravenous injection, in doses of 0.01-10 mg/kg
body weight, preferably of 0.14 - 5 mg/kg and most preferably
of 0.3 - 3 mg/kg.   The antibodies can be given as an
intravenous bolus injection, *e.g.*, over 1 - 5 min., as
repeated injections of smaller doses, or as an intravenous
15   infusion.   The bolus injection is especially useful for the
prophylactic dose or in an emergency.   Further doses of
antibodies can be repeated (*e.g.*, every 4 - 24 hr) during and
after thrombolytic or angioplastic treatment of acute
myocardial infarction at the same proportions as described
20   above to achieve optimal plasma levels of the antibody.
Thrombolytic agents are drugs having the capacity,
directly or indirectly, to stimulate dissolution of thrombi *in
vivo*.   Thrombolytic agents include tissue plasminogen
activator (*see* EP-B 0 093 619), activase, alteplase,
25   duteplase, silteplase, streptokinase, anistreplase, urokinase,
heparin, warfarin and coumarin.   Additional thrombolytic
agents include saruplase and vampire bat plasminogen
activator.   *See* Harris, *Protein Engineering* 6:449-458 (1987);
PCT/EP 90/00194; US Patent 4,970,159.   Thrombolytic agents are
30   administered to a patient in an amount sufficient to partially
disperse, or prevent the formation of, thrombi and their
complications.   An amount adequate to accomplish this is
defined as a "therapeutically effective dose" or "efficacious
dose."   Amounts effective for this use will depend upon the
35   severity of the condition, the general state of the patient,
the route of administration and combination with other drugs.
Often, therapeutically effective doses of thrombolytic agents
and administration regimens for such agents with crossreacting

34

antibodies to E-selectin and P-selectin are those approved by
the FDA for independent uses of thrombolytic agents, *e.g.*, 100
mg of alteplase or 1.5 million IU of streptokinase.

5   VI.   Methods of Diagnosis

The monoclonal antibodies of the present invention
are useful for diagnosing the inflammatory conditions
discussed above and monitoring the treatment thereof. The
antibodies detect P-selectin and E-selectin in a tissue sample
10   such as serum or endothelial cells, *e.g.*, by ELISA or RIA.
The presence of either selectin is diagnostic of inflammation.
Selectin levels may be employed as a differentiation marker to
identify and type cells of certain lineages and developmental
origins.
15   In such procedures, the antibody can be labelled
directly (*e.g.*, by radioactive or fluorescent label) and
immune complexes detected via the label. Usually, however,
the antibody is unlabelled and the desired antigen-monoclonal
antibody complex is detected with an enzyme-conjugated
20   antibody against the monoclonal antibody. Diagnosis can also
be achieved by *in vivo* administration of a labelled
crossreacting P-selectin/E-selectin antibody and detection by
in vivo imaging. The concentration of antibody administered
should be sufficient that the binding to cells having the
25   target antigen is detectable compared to the background
signal. The diagnostic reagent can be labelled with a
radioisotope for camera imaging, or a paramagnetic isotope for
magnetic resonance or electron spin resonance imaging.

30   VII.   Other Uses

The antibodies are also useful for affinity purification
of selectins and cells expressing the same on their external
surfaces. The antibodies can also be used to generate anti-
idiotypic antibodies that mimic a selectin domain responsible
35   for antibody binding. Anti-idiotypic antibodies are useful as
competitive inhibitors of selectin binding. For example, an
anti-idiotypic antibody to a crossreacting P-selectin,

E-selectin monoclonal antibody can be selected to compete with
P-selectin and/or E-selectin for binding to their
counterreceptors. The antibodies are also useful in screening
for a therapeutic agent having the same binding specificity as
5   a crossreacting antibody (see Section I. E).

      The following examples are provided to illustrate
but not to limit the invention:

Example 1: Preparation of Cells Transfected With Selectins

10   L1-2 murine pre-B cell selectin transfectants are
obtained by inserting the respective human selectin genes
downstream of the LCMV promoter in pMRB101 or similar plasmid
(pMRB101 is a derivative of EEb which contains the E. coli gpt
gene. Mulligan et al., Proc. Natl. Acad. Sci. USA 78:2072-
15   2076 (1981); Stephans et al., Nucleic Acids Research 17:7110
(1989)). Plasmid DNA is introduced into L1-2 cells by
standard methods, such as electroporation, and the cells are
selected for resistance to mycophenolic acid. Cells
expressing high levels of the appropriate selectin are further
20   selected by "panning" or fluorescence activated cell sorting
techniques. See Lymphocytes, A Practical Approach (G.C.B.
Klaus, IRL Press, Oxford, England, 1987).

Example 2: Production of Crossreacting Monoclonal Antibodies

25   Crossreacting antibodies were produced using two
different immunization procedures. In all of these
procedures, the inoculum was 10^7 L1-2 selectin transfectant
cells (Berg et al., 1991, 1992, supra) in PBS per injection
into mice. In one procedure, Balb/c mice at 4-6 weeks of age
30   (Simonson Labs, Gilroy, CA) were injected IP with
L1-2$^{E\text{-selectin}}$ transfectants at day 0 and day 14, and
L1-2$^{P\text{-selectin}}$ transfectants at day 46, followed by fusion of
spleen cells on day 50. In a second procedure, C57/Ld mice at
4-6 weeks of age (Jackson Labs, Bar Harbor, ME) were immunized
35   in the footpad with hypotonically lysed L1-2$^{E\text{-selectin}}$ cells on
day 0, then with intact L1-2$^{E\text{-selectin}}$ cells on days 3 and 6,
and with L1-2$^{P\text{-selectin}}$ cells on day 9. The draining lymph
node lymphocytes were fused on day 12. In each procedure,

36

mouse B-cells were fused with P3X mouse myeloma cells using
polyethylene glycol.

     Hybridoma supernatants were screened for specific
binding to both E- and P-selectin by two-color FACS analysis.
5     $L1-2^{P-selectin}$ and $L1-2^{control}$ transfectants were biotinylated by
incubation with amino hexanoyl-biotin-N-hydroxy succinimide
(Zymed Labs, South San Francisco, CA) at 10 μg/ml in PBS pH
8.0 for 25 min, at RT. After washing, 2 x 10^7 cells/ml were
incubated with FITC-Z-Avidin (Zymed Labs, So. San Francisco,
10   CA) diluted 1:150 for $L1-2^{P-selectin}$ cells and 1:1000 for
$L1-2^{control}$ cells in FACS Buffer (2% BSA/PBS/10 mM NaN_3) for 30
min at 4 °C. After washing, cells were mixed with unlabelled
$L1-2^{E-selectin}$ cells at a 1:1:1 ratio in FACS Buffer. 50 μl
hybridoma supernatants were added to 200,000 mixed cells in 50
15   μl in 96-well plates and incubated for 1 hr on ice. After
washing, secondary agent was added, 50 μl of 1:500 Goat
F(ab')2 anti-mouse IgG-PE conjugated (TAGO, Burlingame, CA)
for 30 min prior to washing and fixation. FACS analysis was
performed on a Becton Dickinson FACScan™ (San Jose, CA),
20   according to standard procedures.

     Supernatants containing antibodies reacting with
both P-selectin and E-selectin were identified by a shift in
red fluorescence of the $L1-2^{E-selectin}$ transfectant (unlabelled
with FITC) and the brightest FITC labelled cells
25   ($L1-2^{P-selectin}$ transfectants). The control L1-2 cells
(moderately labelled with FITC) did not show a shift in red
fluorescence, indicating that binding was specific for
P-selectin and E-selectin. The yield of crossreacting
antibodies as a ratio of supernatants screened was 1/844 and
30   2/57 for the two immunization schedules.

     Supernatants showing binding to P-selectin and
E-selectin transfectants were subcloned by limiting dilution
and grown in serum free medium containing residual amounts of
FBS. Three E-/P-selectin cross-reacting antibodies,
35   designated 5C7.29, 1D8.10 and 2C9.11, were purified from these
supernatants on Protein A-Sepharose (Pierce) according to the
recommended protocol. Two antibodies reacting only with
E-selectin, 1E4 and 2D4, and an antibody reacting only with

P-selectin, 5F4, were identified by the same method. The
isotypes of 5C7.29, 1D8.10, 2C9.11, 1E4, and 5F4 were
determined to be IgG1, and that of 2D4 was determined to be
IgG2a using an Innogenetics Inno-Lia mouse monoclonal antibody
5   isotyping kit (Biosource International, Camarillo, CA).
          The three E-/P-selectin crossreacting antibodies
were also tested for their ability to bind to the natural
ligands, rather than the recombinant forms used in the initial
screening assays, by single color FACS analysis. The source
10   of natural E-selectin used in these tests was TNF-α-activated
human umbilical vein endothelial cells (HUVEC). In activated
form, HUVEC cells express E-selectin, but do not express
appreciable amounts of P-selectin. Fig. 1b shows that the
E-/P-cross-reactive antibody 5C7.29 reacts with TNF-α
15   activated HUVEC (shown by black histograms) but not
unactivated HUVEC (grey histograms). Similar results were
obtained for the two other cross-reacting antibodies 2C9.11
and 1D8.10. The activated cells also reacted with the
anti-E-selectin blocking antibody H18/7 (Fig. 1a) (Becton
20   Dickinson (San Jose, CA)), but not with P-selectin-specific
antibodies WAPS 12.2 and 5F4. (WAPS 12.2, a P-selectin
blocking antibody, was provided by R. Aaron Warnock and Eugene
C. Butcher (Stanford, CA).)
          The source of natural P-selectin used in these tests
25   was thrombin-activated platelets. Fig. 2b shows that 5C7.29
binds to these cells as does the known P-selectin antibody
WAPS 12.2 (Fig. 2a). Similar results were obtained with
2C9.11 and ID8.10. Platelets did not significantly react with
anti-E-selectin antibodies H18/7 or 1E4.
30   The E-/P-selectin crossreacting antibodies were
further analyzed for binding to L1-2$^{\text{L-selectin}}$ transfectants,
and with normal human lymphocytes. Specific binding was not
observed, demonstrating that the antibodies are specific for
E- and P-selectins and do not bind to L-selectin.
35   To confirm that the crossreacting antibodies were
truly monoclonal, preclearing experiments were performed. 10
ng antibody (a limiting amount) was incubated with a large
number (10^7) of L1-2$^{\text{E-selectin}}$ cells or L1-2$^{\text{P-selectin}}$ cells for

38

1 hr.   The supernatant was then transferred to a second
aliquot of L1-2$^{E\text{-selectin}}$ cells or L1-2$^{P\text{-selectin}}$ cells (the same
cell type as before) and incubated for 1 hr. Supernatant was
transferred to a third aliquot of cells of the same type as
5   before for a further 1 hr incubation. Supernatant was then
removed and examined for reactivity with L1-2$^{E\text{-selectin}}$,
L1-2$^{P\text{-selectin}}$ or L1-2 untransfected cells by one-color FACS
analysis.

            Fig. 3 shows that preincubation of a solution of the
10   5C7.29 antibody with L1-2$^{P\text{-selectin}}$ transfectants eliminated
subsequent reactivity for both P-selectin and E-selectin.
Similar results were found following preincubation with
L1-2$^{E\text{-selectin}}$ transfectants. These results would be obtained
only if the antibody bound to both selectins, and not if the
15   antibody were a mixture of two different antibodies, one
reactive with E-selectin and one reactive with P-selectin.
Therefore, the dual specificities of 5C7.29 reside in the same
antibody. Similar results were obtained for the 2C9.11 and
1D8.10 antibodies.
20

Example 3:   Inhibition of E-Selectin-Mediated Functions
            The antibody 5C7.29 was tested for the ability to
block E-selectin mediated functions. In one assay, the
antibody was tested for inhibition of HL-60 binding to tumor
25   necrosis factor-α (TNF-α) activated human umbilical vein
endothelial cells (HUVEC). This binding assay simulates the
binding of neutrophils to endothelial cells in an inflammatory
response. The HL-60 cells are a promyelocytic cell line
derived from a patient with acute promyelocytic leukemia.
30   Collins et al., *Nature* 270, 347-349 (1977). The HUVEC cells
are endothelial cells that when activated with TNF-α for 4-6
hours express E-selectin, and not P-selectin.
            HUVEC were obtained from Clonetics (San Diego, CA)
and cultured as suggested. Confluent cultures, up to
35   passage 6, grown in 8 well plastic Lab Tek slides (Nunc,
Naperville, IL) were activated for 4 hours with 1 ng/ml TNF-α
(R&D Systems, Minneapolis, MN). HUVEC cultures were washed
and incubated in 0.15 ml Assay Buffer (10% normal bovine

serum/ 10% normal rabbit serum/10 mM HEPES, pH 7.2/RPMI)
containing antibodies at 17 μg/ml (*i.e.*, in excess) for 20
min.

HL-60 cells were fluorescently labelled with
5   6-carboxyfluorescein diacetate acetoxy-methyl ester (CFDA-AM,
Molecular Probes, Eugene OR) (von Andrian et al., 1991, *supra*)
by a 30 min incubation in 10 mg/ml RPMI/10 mM HEPES, pH 7.2,
washed and resuspended in Assay Buffer and incubated at RT for
20 min. The resuspended cells (6 x 10^5 cells in 0.15 ml) were
10   then added to the HUVEC cultures.

Slides were rotated at 50 rpm on a rotator (Innova
200, New Brunswick Inc.) for 15 min at RT. The cover slips
were removed and non-adherent HL-60 cells washed off by
dipping slides in DMEM. Adherent cells were fixed by
15   immersion in 1% paraformaldehyde-PBS. Slides were examined
microscopically and the number of bound cells per field
determined. Two treatments per slide (in quadruplicate) were
analyzed.

Fig. 4 shows that the number of HL-60 cells binding
20   to the activated HUVEC was decreased 47% by preincubation with
5C7.29. This compared favorably with blocking by the
anti-E-selectin-specific antibody H18/7 (38%). Binding was
not significantly reduced by a control antibody.

Because HUVEC can also express P-selectin (although
25   only at low levels under the present activation conditions),
5C7.29 was also tested for HL-60 binding to CHO cells
transfected with E-selectin. CHO cells permanently
transfected with a truncated form of E-selectin containing the
first four N-terminal domains of E-selectin fused to the
30   transmembrane and cytoplasmic domain of another protein were
produced according to standard methods. Expression was
confirmed by reactivity with a control anti-E-selectin
antibody (H18/7). Inhibition of binding between fluorescently
labelled HL-60 and the transfected CHO cells was performed
35   using the same assay as for the TNF-α-activated HUVEC. 5C7.29
was found to block adhesion by 82% (Fig. 5). Similar results
were observed with 1D8.10, 2C9.11 and the E-selectin blocking

antibody 1E4. The non-blocking P-selectin specific control
antibody 5F4 had no significant effect in this assay.

   The cross-reacting antibodies also blocked normal
human peripheral blood neutrophil binding to TNF-α-activated

5 HUVEC. At a final concentration of 10 μg/ml, 5C7.29 blocked
71 +/-13%, 2C9.11 blocked 62 +/-8% and 1D8 blocked 52 +/-10%
of neutrophil binding to activated HUVEC, while the
anti-E-selectin antibodies 1E4 and H18/7 (Bevilacqua et al.,
1987, *supra*) blocked 68+/-4% and 68 +/-15%, and a control

10 mouse IgG1 antibody did not block (-21% +/-11%), n=4. For
these experiments, neutrophils were isolated from normal human
blood by density gradient centrifugation and dextran
sedimentation by standard procedures (*Current Protocols in
Immunology*, Coligan et al., eds., John Wiley and Sons, New

15 York, 1992). Assays were performed as for HL-60 cells except
neutrophils were added to HUVEC at 7.5 X 10^4 in 0.15 ml.

Example 4: Inhibition of P-selectin-Mediated Functions

   The antibodies 5C7.29, 2C7.11 and 1D8.10 were tested

20 for their ability to block P-selectin-mediated functions.
Blocking was tested in a platelet-HL-60 rosette assay (Corral
et al., 1990, *supra*). The platelets provide a source of cells
expressing P-selectin and the HL-60 cells simulate
neutrophils. Normal human blood was collected with sodium

25 citrate as anticoagulant and the platelet-rich plasma (PRP)
prepared by centrifugation at 250g for 10 min. Platelets were
isolated from PRP by centrifugation at 1000g for 20 min and
resuspended at 3 x 10^8/ml in PBS, pH 7.2. Monoclonal
antibodies (1 μg in 20 μl, *i.e.*, an excess) were added to

30 20 μl platelets. In some experiments normal human thrombin
(0.3 U/μl) was added to activate the platelets as described by
Corral et al., 1990, *supra*. After 45 min, 20 μl HL-60 cells
(10^6/ml in PBS) were added and further incubated for 45 min.
Bound platelets were fixed to HL-60 cells by addition of

35 glutaraldehyde to 1.25%. At least 100 HL-60 cells for each
sample were observed microscopically and the number of cells
with bound platelets (>2 platelets per HL-60 cell) determined.

Fig. 6 shows that all three crossreacting antibodies block rosetting to about the same extent as the P-selectin specific blocking antibody WAPS 12.2. Similar blocking experiments can be performed using human peripheral blood

5   neutrophils in place of HL-60 cells. Neutrophils are prepared by the same method and used at the same concentration as described in Example 3.

Example 5:   Cloning and sequencing of mouse 5C7.29 heavy
10   chain and light chain variable region cDNA

cDNAs for the heavy chain and light chain variable region genes of the mouse 5C7.29 antibody were cloned using anchored polymerase chain reactions as described (see Co et al., *J. Immunol.* 148: 1149 (1992)), using 3' primers that

15   hybridized to the constant regions and contained HindIII sites, and 5' primers that hybridized to the dG tails and contained EcoRI sites. The PCR amplified fragments were digested with EcoRI and HindIII and cloned into the pUC18 or pUC19 vectors for sequencing. At least two gamma-1 specific

20   and two kappa specific clones were sequenced. The gamma-1 clones and the kappa clones are respectively identical in sequence. The variable region cDNA sequences and the deduced amino acid sequences for the gamma-1 and kappa chains are shown in Fig. 7A-7B [SEQ ID NOS:1-4].

25

Example 6:   Design of humanized 5C7.29 antibody variable
                       domain

Based on a sequence homology search against the NBRF protein sequence database, the variable regions of light chain

30   subclass I and heavy chain subclass III show good homology to the mouse 5C7.29 antibody. In particular, the antibody III-3R provides the best framework homology with 5C7.29 and was chosen to provide the framework sequences for humanization of 5C7.29. However, other members of the light chain subclass I

35   and heavy chain subclass III would also be especially suitable for use in providing the frameworks of the respective humanized 5C7.29 chains.

The computer program ENCAD (M. Levitt et al., J. Mol. Biol. 168: 595 (1983)) was used to construct a molecular

42

model of the 5C7.29 variable domain. The program ABMOD (B.T.
Zilber et al. *Biochem.* 29:10032-41) is also useful. The model
was used to determine the amino acids in the 5C7.29 framework
that were close enough to the CDRs to potentially interact
5   with them. To design the humanized light and heavy chain
5C7.29 variable regions, the CDRs from the mouse 5C7.29
antibody were grafted into the framework sequences of the
III-3R antibody. At framework positions where the model
suggested contact with the CDRs, the amino acids from the
10   mouse 5C7.29 antibody were chosen to replace the residues in
the III-3R sequence. For humanized 5C7.29, this was done at
residues 69 and 70 in the light chain and at no residues in
the heavy chain. Moreover, at some positions where the amino
acid was unusual for human antibodies at that position, an
15   amino acid representing a consensus among the relevant human
subclass was substituted for the III-3R framework residue.
For humanized 5C7.29, this was done at residues 61, 72, 82 and
99 in the light chain and residues 1, 75 and 78 in the heavy
chain.
20   The final sequence of the humanized 5C7.29 heavy and
light chain variable region is shown in Figs. 8A-8B [SEQ ID
NOS:5-8]. However, many of the potential CDR-contact residues
are amenable to substitutions of other amino acids and may
still allow the antibody to retain substantial affinity to the
25   antigens. The following table lists a number of positions in
the framework where alternative amino acids may be suitable
(note LC = light chain, HC = heavy chain):

Position	Humanized 5C7.29	Alternatives
LC-1	D	Q
LC-3	Q	V
LC-4	M	L
LC-59	S	A
LC-69	S	D
LC-70	Y	F
HC-49	A	S
HC-84	N	T

Likewise, many of the framework residues not
contacting the CDRs in the humanized 5C7.29 heavy and light
5   chains are also amenable to substitutions with amino acids
from either the human III-3R antibody, or from the
corresponding position of other human antibodies, or from the
mouse 5C7.29 or other mouse antibodies, while still preserving
substantial affinity and non-immunogenicity of the humanized
10   antibody. The following table lists a number of positions in
the framework where alternative amino acids may be suitable:

Position	Humanized 5C7.29	Alternatives
LC-61	F	I
LC-72	L	F
LC-82	F	I,A
LC-99	Q	G,S
HC-1	E	Q,D
HC-75	S	A,P
HC-78	T	S
HC-116	A	S

25   Finally, even certain residues in the CDRs may be
substituted with other residues while the antibody may retain
substantially the same affinity and specificity. Structure-
function studies of antibody binding reveal that not all of
the CDR amino acids participate equally in specifying affinity
30   towards a given antigen (or set of related antigens). These
studies enable prediction with some reliability of particular
CDR positions least likely to change substantially the binding
characteristics of an antibody. For example, Chothia and co-
workers define structurally acceptable amino acids in CDR
35   positions (Chothia et al., *J. Mol. Biol.* 196: 902 (1987);
Chothia et al., *Nature* 342: 877 (1989); and Tramontano et al.,
Proteins: Struct. Funct. Genet. 6: 382 (1989)), and many of
these are not accessible to solvent (i.e, available to

44

participate in binding), in the model of 5C7.29.   Other
workers have shown that residues 61-66 of CDR H2 may not
participate in antigen binding (Carter et al., *Proc. Natl.
Acad. Sci. USA* 89: 4285 (1992); Hsiao et al., *Protein Eng.*
7:815 (1994)).   Surveys of antibody-antigen complex structures
support this notion (Glaser et al., *J. Immunol.* 149: 2606
(1992); Padlan, *Mol. Immunol.* 31: 169 (1994)).   Some of these
CDR residues that may be changed in humanized 5C7.29 and their
potential substitutions are listed in the following table:

CDR	Position	Humanized 5C7.29	Alternatives
L1	29	V	I,L
	32	M	L
L2	53	L	any
	88	A	any
	55	S	T
L3	88	Q	N,H
	89	Q	N,H
H1	34	M	I,V,L
H2	61	A	any
	62	T	any
	63	T	any
	64	V	A,I,L,M,F
	65	R	K,Q
	66	G	A,D,T,S

        Selection of various combinations of alternative
amino acids may be used to produce versions of humanized
5C7.29 that have varying combinations of affinity,
specificity, non-immunogenicity, ease of manufacture and other
desirable properties.   The above examples are offered by way
of illustration, not of limitation.

Example 7:   Construction of humanized 5C7.29
        For the construction of variable region genes for
the humanized 5C7.29 antibody, nucleotide sequences were

selected that encode the protein sequences of the humanized
heavy and light chains, including the signal peptide,
generally utilizing codons found in the mouse sequence.
Several degenerate codons were changed to create restriction
5   sites or to remove undesirable ones. The nucleotide sequences
of the genes also included splice donor signals and an XbaI
site at each end. The nucleotide sequences and encoded light
and heavy chain variable regions of the humanized 5C7.29
antibody are shown in Figs. 8A-8B [SEQ ID NOS:5-8].
10 .   Each gene was constructed from eight overlapping
synthetic oligonucleotides. Assembly and amplification of the
genes were carried out in four steps as shown in Fig. 9:
(1) the four pairs of complementary oligonucleotides were
annealed and extended with Klenow polymerase in separate
15   reactions; (2) the resulting four double-stranded DNA
fragments were mixed in pairs, denatured, re-annealed and
extended in two separate reactions using Klenow fragment;
(3) the resulting two double-stranded half-gene fragments were
mixed, denatured, re-annealed and extended to create the full
20   length double stranded variable region genes; (4) the gene
fragments were finally amplified, using Taq polymerase and two
primers that hybridize to the 5' and the 3' end of the
variable region genes and contain XbaI sites for cloning into
the respective expression vectors, pVk and pVg4. Reactions
25   were carried out under conditions well-known in the art.
The pVk vector for light chain expression and the
pVg1 vector for heavy chain expression have been previously
described (see Co et al., *J. Immunol.* 148: 1149 (1992)). To
produce a humanized 5C7.29 antibody of the IgG4 isotype, the
30   heavy chain expression vector pVg4 has been constructed. To
do so, the XbaI-BamHI fragment of pVg1 containing the γ1
constant region was replaced with an approximately 2000 bp
fragment of the human γ4 constant region gene (Ellison and
Hood, *Proc. Natl. Acad. Sci USA* 79:1984 (1982)) that extended
35   from the HindIII side preceding the CH1 exon of the γ4 gene to
270 bp after the NsiI site following the CH4 exon of the gene,
using methods well-known to those skilled in the art,
including polymerase chain reaction.

The heavy chain and light chain plasmids were transfected into a mouse myeloma cell line Sp2/0-Ag14 (ATCC CRL 1581). Transfection was by electroporation using a Gene Pulser apparatus (Bio-Rad) at 360 V and 25 uFD capacitance

5 according to the manufacturer's instructions. Before transfection, the light chain- and heavy chain-containing plasmids were linearized using PvuII, extracted with phenol-chloroform, and ethanol-precipitated. All transfections were done using 30-50 μg plasmid DNA and about 10^7 cells in PBS.

10 The cells from each transfection were plated into 2 to 4 96-well tissue culture plates. After 48 hours, selective medium was applied.

Cells were selected for gpt expression in DMEM + 10% FBS + HT media supplement (Sigma) + 1 μg/ml mycophenolic acid.

15 Antibody-producing clones were screened by assaying human antibody production in the culture supernatant by ELISA. Antibody from the best-producing clones was purified by passing tissue culture supernatant over a column of protein A-Sepharose CL-4B (Pharmacia). The bound antibodies were

20 eluted with 0.2 M glycine-HCl, pH 3.0, and neutralized with 1 M Tris-HCl, pH 8.0. The buffer was exchanged into phosphate buffered saline (PBS) by passing over a PD10 column (Pharmacia), or by dialysis. To obtain cells producing higher levels of antibody, the transfected clones may be cultured in

25 increasing concentrations of methotrexate.

Example 8: Properties of humanized 5C7.29

To show that humanized 5C7.29 specifically binds to E-selectin and P-selectin, L1-2$^{E-selectin}$ and L1-2$^{P-selectin}$

30 transfectants were incubated with humanized 5C7.29 or control antibodies for 1 hour. After washing, cells were incubated in a 1:400 dilution of phycoerythrin-conjugated anti-human Ig (Biosource, Camarillo, CA), washed, then analyzed for fluorescence by flow cytometry (FACS) as previously described

35 (Berg et al., *Blood* 85: 31 (1995)). Humanized 5C7.29 reacts with both L1-2$^{E-selectin}$ and L1-2$^{P-selectin}$ transfectants, but not L1-2$^{L-selectin}$ transfectants (Fig. 10) demonstrating that the humanization process did not result in loss of either

E-selectin or P-selectin binding or gain in the ability to bind L-selectin.

The affinity of the humanized 5C7.29 antibody for E-selectin and P-selectin was separately determined by competition with the radio-iodinated mouse 5C7.29 antibody (Fig. 11). Purified mouse 5C7.29 antibody was labeled with $Na^{125}I$ (Amersham, Arlington Heights, IL) using the lactoperoxidase procedure to 4 mCi/mg of protein. $CHO^{E-selectin}$ cells and $L1-2^{P-selectin}$ cells, which were obtained by transfecting the E-selectin and P-selectin genes into the respective host cells CHO and L1-2 (Gallatin et al., Nature 304:30 (1983)) by methods well known in the art (see, e.g., Larsen et al., *J. Biol. Chem.* 267: 11104 (1992)), were used as sources for E-selectin and P-selectin. Increasing amounts of competitor antibody (mouse 5C7.29 or humanized 5C7.29) were added to 2 ng of radio-iodinated tracer mouse 5C7.29 antibody and incubated with 4 X 10^5 $CHO^{E-selectin}$ cells or $L1-2^{P-selectin}$ cells in 0.2 ml of binding buffer (PBS with 2% fetal calf serum, 0.1% sodium azide) for 2 hours at 4° C with constant shaking. Cells were then washed and centrifuged, and their radioactivities measured. The ratio of bound and free tracer antibody were calculated (Figs. 11A and 11B).

The binding affinities were calculated according to the methods of Berzofsky and Berkower (J. A. Berzofsky and I. J. Berkower, in *Fundamental Immunology* (ed. W.E. Paul), Raven Press (New York), p. 595 (1984)). The humanized 5C7.29 had an affinity of approximately 3 x 10^8 M^{-1} for E-selectin, with no significant difference from that of mouse 5C7.29, and an affinity of approximately 1.3 X 10^8 M^{-1} for P-selectin, within about 3 to 4-fold of the mouse 5C7.29 antibody. This experiment also shows directly that humanized 5C7.29 has the ability to compete with the mouse 5C7.29 antibody for binding to both E-selectin and P-selectin. In another experiment, the affinities of mouse and humanized 5C7.29 for P-selectin were determined by the method of Scatchard (Berzofsky and Berkower, *supra*) to be approximately 1.9 x 10^8 M^{-1} and 6 x 10^8 M^{-1}, respectively, in good agreement with the results of the competitive binding experiment.

48

To show that the humanized 5C7.29 antibody inhibits binding of E-selectin to a counter-receptor for E-selectin, its ability to inhibit the binding of HL-60 cells to E-selectin transfectant cells was determined. Assays of the

5   adhesion of HL-60 cells with CHO$^{E\text{-selectin}}$ cells were performed as previously described (Berg et al., *Blood* 85: 31 (1995), and *supra*) in the presence of monoclonal antibodies at the indicated concentrations. Fig. 12 shows that humanized 5C7.29 blocks binding of HL-60 cells to CHO$^{E\text{-selectin}}$ transfectants as

10   well as mouse 5C7.29. For the representative experiment shown, two treatments per slide (each treatment in quadruplicate) were analyzed and the mean and standard deviations calculated. An isotype-matched control antibody did not affect binding.

15   To show that the humanized 5C7.29 antibody inhibits binding of P-selectin to a counter-receptor for P-selectin, its ability to inhibit the binding of HL-60 cells and activated platelets was determined. Assays of the rosetting of activated platelets to the HL-60 cells were performed as

20   described (Berg et al., *Blood* 85:31 (1995) and *supra*) in the presence of monoclonal antibodies at the indicated concentrations. Fig. 13 shows that humanized 5C7.29 blocks binding of platelets to HL-60 cells as well as mouse 5C7.29. An isotype-matched control antibody had no affect on binding

25   in this assay. The representative experiment shown was performed in triplicate and the mean and standard deviations calculated.

Example 9: Epitope mapping of 5C7.29

30   To determine the amino acids of E-selectin involved in the binding of 5C7.29 (the epitope), the following procedure was used. DNA encoding the lectin and EGF-like domains of human E-selectin were fused to a gene encoding the human immunoglobulin lambda constant region (C_λ), which served

35   as a tag. The chimeric DNA was inserted in a plasmid vector, which provided a lac promoter and pelB signal sequence for expression and secretion of the chimeric (fusion) protein in *E. coli*. The E-selectin domains were randomly mutagenized by

error-prone polymerase chain reaction (PCR) utilizing AmpliTaq
enzyme (Perkin Elmer) and Mn^{++}, and the amino acid
substitutions were determined by DNA sequencing. *E. coli*
strain TG1ΔrecA was transformed with the wild-type and mutant

5   plasmids, and chimeric proteins were overexpressed by growing
transformed *E. coli* in 2YT broth. After 8 hours of induction
with 1mM IPTG, culture supernatants containing the chimeric
proteins were collected. All operations were performed
according to methods well-known in the art of molecular

10   biology.

        Next, 96-well plates were coated with the 5C7.29
antibody (or control antibodies). After blocking, the plates
were incubated with the *E. coli* supernatants and then with
HRP-conjugated anti-human C_λ antibodies (Biosource, Camarillo,

15   CA). After washing, bound enzyme was detected with TMB
substrate. Supernatants containing mutant E-selectin-C_λ
chimeric protein to which 5C7.29 could still bind gave a
positive signal, while supernatants containing mutant
E-selectin to which 5C7.29 could not bind gave a negative

20   signal. The results are shown in the following table, where
the symbol AXB means a mutant in which the Xth amino of
E-selectin form the mature N-terminus is changed from the
normal A to mutant B.

	Mutant	Reactivity
25	Q21R	−
	R22G	−
	Y23H	−
30	Y48H	+
	E92G	+
	N105S	+
	K111E	+
	T119A	−
35	A120T	−

50

Because mutating amino acids Q_{21}, R_{22}, Y_{23}, T_{119} and A_{120} in E-selectin prevented binding of antibody 5C7.29, these amino acids must be in the epitope of 5C7.29. The full amino acid sequence of E-selectin is given in Bevilacqua, *supra* and

5   in United States Patent 5,272,263 (ELAM-1). (Another anti-E-selectin antibody was able to bind to these mutants, showing that they did not disrupt the overall structure of E-selectin). Other E/P cross-reacting antibodies that show a different pattern of reactivity with these E-selectin mutants

10   must have a different epitope in E-selectin. The epitope of 5C7.29 in P-selectin may be determined by a similar procedure using P-selectin mutants, and may be similarly compared to the epitope of other E/P cross-reacting antibodies. The epitopes of 5C7.29 in E-selectin and P-selectin are preferred epitopes,

15   because antibodies such as 5C7.29 that bind to them may have high affinity and blocking activity.

While the foregoing invention has been described in some detail for purposes of clarity and understanding, it will be clear to one skilled in the art from a reading of this

20   disclosure that various changes in form and detail can be made without departing from the true scope of the invention. All publications and patent documents cited in this application are incorporated by reference in their entirety for all purposes to the same extent as if each individual publication

25   or patent document were so individually denoted.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

    (i) APPLICANT: Berg, Ellen L.

    (ii) TITLE OF INVENTION: Cross-Reacting Monoclonal Antibodies
        Specific for E-Selectin and P-Selectin

    (iii) NUMBER OF SEQUENCES: 10

    (iv) CORRESPONDENCE ADDRESS:
        (A) ADDRESSEE: Townsend and Townsend Khourie and Crew
        (B) STREET: One Market Plaza, Steuart Tower, Suite 2000
        (C) CITY: San Francisco
        (D) STATE: California
        (E) COUNTRY: USA
        (F) ZIP: 94105

    (v) COMPUTER READABLE FORM:
        (A) MEDIUM TYPE: Floppy disk
        (B) COMPUTER: IBM PC compatible
        (C) OPERATING SYSTEM: PC-DOS/MS-DOS
        (D) SOFTWARE: PatentIn Release #1.0, Version #1.25

    (vi) CURRENT APPLICATION DATA:
        (A) APPLICATION NUMBER: WO
        (B) FILING DATE:
        (C) CLASSIFICATION:

    (vii) PRIOR APPLICATION DATA:
        (A) APPLICATION NUMBER: 08/259,963
        (B) FILING DATE: 14-JUNE-94

    (viii) ATTORNEY/AGENT INFORMATION:
        (A) NAME: Smith, William M.
        (B) REGISTRATION NUMBER: 30,223
        (C) REFERENCE/DOCKET NUMBER: 11823-005810PC

    (ix) TELECOMMUNICATION INFORMATION:
        (A) TELEPHONE: 415-326-2400
        (B) TELEFAX: 415-326-2422

(2) INFORMATION FOR SEQ ID NO:1:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 384 base pairs
        (B) TYPE: nucleic acid
        (C) STRANDEDNESS: single
        (D) TOPOLOGY: linear

    (ii) MOLECULE TYPE: cDNA

    (ix) FEATURE:
        (A) NAME/KEY: CDS
        (B) LOCATION: 1..384

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```
ATG GAT TTT CAA GTG CAG ATT TTC AGC TTC CTG CTA ATC AGT GCC TCA      48
Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser
 1           5               10              15

GTC ATA ATA TCC AGA GGA CAA ATT GTT CTC ACC CAG TCT CCA GCA ATC      96
Val Ile Ile Ser Arg Gly Gln Ile Val Leu Thr Gln Ser Pro Ala Ile
         20              25              30

ATG TCT GCA TCT CCA GGG GAG AAG GTC ACC ATG ACC TGC AGT GCC AGC     144
Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Ser Ala Ser
         35              40              45

TCA AGT GTG CCT TAC ATG CAC TGG TAT CAG CAG AAG TCA GGC ACC TCC     192
Ser Ser Val Pro Tyr Met His Trp Tyr Gln Gln Lys Ser Gly Thr Ser
         50              55              60

CCC AAA TTA TGG ATT TAT GAC ACA TCC AAT CTG GCT TCT GGA GTC CCT     240
Pro Lys Leu Trp Ile Tyr Asp Thr Ser Asn Leu Ala Ser Gly Val Pro
65              70              75              80

GCT CGC TTC AGT GGC AGT GGG TCT GGG ACC TCT TAC TCT CTC ACA ATC     288
Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile
             85              90              95

AGC AGC ATG GAG GCT GAA GAT GCT GCC ACT TAT TAC TGC CAG CAG TGG     336
Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp
             100             105             110

AGT AGT GAC CCA TTC ACG TTC GGC TCG GGG ACA AAG TTG GAA ATA AAG     384
Ser Ser Asp Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
             115             120             125
```

(2) INFORMATION FOR SEQ ID NO:2:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 128 amino acids
        (B) TYPE: amino acid
        (D) TOPOLOGY: linear

    · (ii) MOLECULE TYPE: protein

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```
Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser
1               5               10                  15

Val Ile Ile Ser Arg Gly Gln Ile Val Leu Thr Gln Ser Pro Ala Ile
            20              25                  30

Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Ser Ala Ser
        35                  40                  45

Ser Ser Val Pro Tyr Met His Trp Tyr Gln Gln Lys Ser Gly Thr Ser
    50                  55                  60

Pro Lys Leu Trp Ile Tyr Asp Thr Ser Asn Leu Ala Ser Gly Val Pro
65                  70                  75                  80

Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile
            85                  90                  95

Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp
        100                 105                 110

Ser Ser Asp Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
    115                 120                 125
```

(2) INFORMATION FOR SEQ ID NO:3:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 405 base pairs
        (B) TYPE: nucleic acid
        (C) STRANDEDNESS: single
        (D) TOPOLOGY: linear

    (ii) MOLECULE TYPE: cDNA

    (ix) FEATURE:
        (A) NAME/KEY: CDS
        (B) LOCATION: 1..405

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

```
ATG GAC TCC AGG CTC AAT TTA GTT TTC CTT GTC CTT ATT TTA AAA GGT          48
Met Asp Ser Arg Leu Asn Leu Val Phe Leu Val Leu Ile Leu Lys Gly
 1               5                  10                  15

GTC CAG TGT GAT GTA CGA CTG GTG GAG TCT GGG GGA GGT TTA GTG CAG          96
Val Gln Cys Asp Val Arg Leu Val Glu Ser Gly Gly Gly Leu Val Gln
                 20                  25                  30

CCT GGA GGG TCC CGG AAA CTC TCC TGT GCA GCC TCT GGA TTC ACT TTC         144
Pro Gly Gly Ser Arg Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
             35                  40                  45

AGT AGC TTT GGA ATG CAC TGG GTT CGT CAG GCT CCT GAT AAG GGG CTG         192
Ser Ser Phe Gly Met His Trp Val Arg Gln Ala Pro Asp Lys Gly Leu
         50                  55                  60

GAG TGG GTC GCA TTC ATT AGC AGT GGC AGT AGT ACC ATC TAC TAT GCT         240
Glu Trp Val Ala Phe Ile Ser Ser Gly Ser Ser Thr Ile Tyr Tyr Ala
65                  70                  75                  80

GAC ACA GTG AGG GGC CGA TTC ACC ATC TCC AGA GAC AGT CCC AAG AAC         288
Asp Thr Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Ser Pro Lys Asn
                 85                  90                  95

ACC CTG TTC CTG CAA ATG ACC AGT CTA AGG TCT GAG GAC ACG GCC ATG         336
Thr Leu Phe Leu Gln Met Thr Ser Leu Arg Ser Glu Asp Thr Ala Met
                100                 105                 110

TAT TAC TGT GCA AGA CCT TTA CCC CCG TTT GCT TAC TGG GGC CAA GGG         384
Tyr Tyr Cys Ala Arg Pro Leu Pro Pro Phe Ala Tyr Trp Gly Gln Gly
            115                 120                 125

ACT TTG GTC ACT GTC TCT GCA                                             405
Thr Leu Val Thr Val Ser Ala
        130                 135
```

(2) INFORMATION FOR SEQ ID NO:4:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 135 amino acids
        (B) TYPE: amino acid
        (D) TOPOLOGY: linear

    (ii) MOLECULE TYPE: protein

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

```
Met Asp Ser Arg Leu Asn Leu Val Phe Leu Val Leu Ile Leu Lys Gly
 1               5                  10                  15

Val Gln Cys Asp Val Arg Leu Val Glu Ser Gly Gly Gly Leu Val Gln
                20              25                  30

Pro Gly Gly Ser Arg Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
        35                  40                  45

Ser Ser Phe Gly Met His Trp Val Arg Gln Ala Pro Asp Lys Gly Leu
    50                  55                  60

Glu Trp Val Ala Phe Ile Ser Ser Gly Ser Ser Thr Ile Tyr Tyr Ala
65                  70                  75                      80

Asp Thr Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Ser Pro Lys Asn
                85                  90                  95

Thr Leu Phe Leu Gln Met Thr Ser Leu Arg Ser Glu Asp Thr Ala Met
            100                 105                 110

Tyr Tyr Cys Ala Arg Pro Leu Pro Pro Phe Ala Tyr Trp Gly Gln Gly
        115                 120                 125

Thr Leu Val Thr Val Ser Ala
    130                 135
```

(2) INFORMATION FOR SEQ ID NO:5:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 384 base pairs
        (B) TYPE: nucleic acid
        (C) STRANDEDNESS: single
        (D) TOPOLOGY: linear

    (ii) MOLECULE TYPE: cDNA

    (ix) FEATURE:
        (A) NAME/KEY: CDS
        (B) LOCATION: 1..384

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

```
ATG GAT TTT CAA GTG CAG ATT TTC AGC TTC CTG CTA ATC AGT GCC TCA      48
Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser
 1               5                  10                  15

GTC ATA ATA TCC AGA GGA GAT ATT CAA ATG ACC CAG TCT CCA TCT AGC      96
Val Ile Ile Ser Arg Gly Asp Ile Gln Met Thr Gln Ser Pro Ser Ser
            20                  25                  30

TTA TCT GCA TCT GTA GGG GAT AGG GTC ACC ATA ACC TGC AGT GCC AGC     144
Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Ser Ala Ser
        35                  40                  45

TCA AGT GTG CCT TAC ATG CAC TGG TAT CAG CAG AAG CCA GGC AAA GCC     192
Ser Ser Val Pro Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Lys Ala
        50                  55                  60

CCC AAA TTA TTG ATT TAT GAC ACA TCC AAT CTG GCT TCT GGA GTC CCT     240
Pro Lys Leu Leu Ile Tyr Asp Thr Ser Asn Leu Ala Ser Gly Val Pro
65                  70                  75                  80

TCT CGC TTC AGT GGC AGT GGG TCT GGG ACC TCT TAC ACT CTC ACA ATC     288
Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Thr Leu Thr Ile
                85                  90                  95

AGC AGC CTG CAG CCT GAA GAT TTT GCC ACT TAT TAC TGC CAG CAG TGG     336
Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Trp
               100                 105                 110

AGT AGT GAC CCA TTC ACG TTC GGC CAG GGG ACA AAG GTG GAA ATA AAG     384
Ser Ser Asp Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
               115                 120                 125
```

(2) INFORMATION FOR SEQ ID NO:6:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 128 amino acids
        (B) TYPE: amino acid
        (D) TOPOLOGY: linear

    (ii) MOLECULE TYPE: protein

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

```
Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser
 1               5                  10                  15

Val Ile Ile Ser Arg Gly Asp Ile Gln Met Thr Gln Ser Pro Ser Ser
              20                  25                  30

Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Ser Ala Ser
          35                  40                  45

Ser Ser Val Pro Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Lys Ala
     50                  55                  60

Pro Lys Leu Leu Ile Tyr Asp Thr Ser Asn Leu Ala Ser Gly Val Pro
 65                  70                  75                  80

Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Thr Leu Thr Ile
              85                  90                  95

Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Trp
         100                 105                 110

Ser Ser Asp Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
         115                 120                 125
```

58

(2) INFORMATION FOR SEQ ID NO:7:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 405 base pairs
        (B) TYPE: nucleic acid
        (C) STRANDEDNESS: single
        (D) TOPOLOGY: linear

   (ii) MOLECULE TYPE: cDNA

   (ix) FEATURE:
        (A) NAME/KEY: CDS
        (B) LOCATION: 1..405

   (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

```
ATG GAC TCC AGG CTC AAT TTA GTT TTC CTT GTC CTT ATT TTA AAA GGT        48
Met Asp Ser Arg Leu Asn Leu Val Phe Leu Val Leu Ile Leu Lys Gly
 1               5                  10                  15

GTC CAG TGT GAA GTA CAA CTG GTG GAG TCT GGG GGA GGT TTA GTG CAG        96
Val Gln Cys Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln
                20                  25                  30

CCT GGA GGG TCC CTT CGT CTC TCC TGT GCA GCC TCT GGA TTC ACT TTC       144
Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
            35                  .40                  45

AGT AGC TTT GGA ATG CAC TGG GTT CGT CAG GCT CCT GGT AAG GGG CTG       192
Ser Ser Phe Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
        50                  55                  60

GAG TGG GTC GCA TTC ATT AGC AGT GGC AGT AGT ACC ATC TAC TAT GCT       240
Glu Trp Val Ala Phe Ile Ser Ser Gly Ser Ser Thr Ile Tyr Tyr Ala
 65                  70                  75                  80

GAC ACA GTG AGG GGC CGA TTC ACC ATC TCC AGA GAC AAC ACC AAG AAC       288
Asp Thr Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
                85                  90                  95

ACC CTG TAT CTG CAA ATG AAC AGT CTA AGG GCT GAG GAC ACG GCC GTG       336
Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
            100                 105                 110

TAT TAC TGT GCA AGA CCT TTA CCC CCG TTT GCT TAC TGG GGC CAA GGG       384
Tyr Tyr Cys Ala Arg Pro Leu Pro Pro Phe Ala Tyr Trp Gly Gln Gly
            115                 120                 125

ACT TTG GTC ACT GTC TCT GCA                                           405
Thr Leu Val Thr Val Ser Ala
            130                 135
```

(2) INFORMATION FOR SEQ ID NO:8:

    (i) SEQUENCE CHARACTERISTICS:
       (A) LENGTH: 135 amino acids
       (B) TYPE: amino acid
       (D) TOPOLOGY: linear

    (ii) MOLECULE TYPE: protein

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

```
Met Asp Ser Arg Leu Asn Leu Val Phe Leu Val Leu Ile Leu Lys Gly
 1               5                  10                  15

Val Gln Cys Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln
            20                  25                  30

Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
        35                  40                  45

Ser Ser Phe Gly Met His Trp Val Arg Gln Ala Pro Asp Lys Gly Leu
    50                  55                  60

Glu Trp Val Ala Phe Ile Ser Ser Gly Ser Ser Thr Ile Tyr Tyr Ala
65                  70                  75                  80

Asp Thr Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
            85                  90                  95

Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
        100                 105                 110

Tyr Tyr Cys Ala Arg Pro Leu Pro Pro Phe Ala Tyr Trp Gly Gln Gly
        115                 120                 125

Thr Leu Val Thr Val Ser Ala
    130                 135
```

(2) INFORMATION FOR SEQ ID NO:9:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 106 amino acids
        (B) TYPE: amino acid
        (C) STRANDEDNESS: single
        (D) TOPOLOGY: linear

   (ii) MOLECULE TYPE: peptide

   (ix) FEATURE:
        (A) NAME/KEY: Region
        (B) LOCATION: one-of(1)
        (D) OTHER INFORMATION: /note= "Xaa is Asp or
            Gln."

   (ix) FEATURE:
        (A) NAME/KEY: Region
        (B) LOCATION: one-of(2)
        (D) OTHER INFORMATION: /note= "Xaa is Gln or Val."

   (ix) FEATURE:
        (A) NAME/KEY: Region
        (B) LOCATION: one-of(4,32)
        (D) OTHER INFORMATION: /note= "Xaa is Met or Leu."

   (ix) FEATURE:
        (A) NAME/KEY: Region
        (B) LOCATION: one-of(29)
        (D) OTHER INFORMATION: /note= "Xaa is Val, Leu or Ile."

   (ix) FEATURE:
        (A) NAME/KEY: Region
        (B) LOCATION: one-of(53,54)
        (D) OTHER INFORMATION: /note= "Xaa is any amino acid."

   (ix) FEATURE:
        (A) NAME/KEY: Region
        (B) LOCATION: one-of(55)
        (D) OTHER INFORMATION: /note= "Xaa is Ser or Thr."

   (ix) FEATURE:
        (A) NAME/KEY: Region
        (B) LOCATION: one-of(59)
        (D) OTHER INFORMATION: /note= "Xaa is Ser or Ala."

   (ix) FEATURE:
        (A) NAME/KEY: Region
        (B) LOCATION: one-of(61)
        (D) OTHER INFORMATION: /note= "Xaa is Phe or Ile."

(ix) FEATURE:
      (A) NAME/KEY: Region
      (B) LOCATION: one-of(69)
      (D) OTHER INFORMATION: /note= "Xaa is Ser or Asp."

(ix) FEATURE:
      (A) NAME/KEY: Region
      (B) LOCATION: one-of(70)
      (D) OTHER INFORMATION: /note= "Xaa is Tyr or Phe."

(ix) FEATURE:
      (A) NAME/KEY: Region
      (B) LOCATION: one-of(72)
      (D) OTHER INFORMATION: /note= "Xaa is Leu or Phe."

(ix) FEATURE:
      (A) NAME/KEY: Region
      (B) LOCATION: one-of(82)
      (D) OTHER INFORMATION: /note= "Xaa is Phe or Ile."

(ix) FEATURE:
      (A) NAME/KEY: Region
      (B) LOCATION: one-of(88,89)
      (D) OTHER INFORMATION: /note= "Xaa is Gln, Asn or His."

(ix) FEATURE:
      (A) NAME/KEY: Region
      (B) LOCATION: one-of(99)
      (D) OTHER INFORMATION: /note= "Xaa is Gln, Gly or Ser."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Xaa Xaa Ile Xaa Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1   5   10   15

Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Xaa Pro Tyr Xaa
            20   25   30

His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
            35   40   45

Asp Thr Ser Asn Xaa Xaa Xaa Gly Val Pro Xaa Arg Xaa Ser Gly Ser
        50   55   60

Gly Ser Gly Thr Xaa Xaa Thr Xaa Thr Ile Ser Ser Leu Gln Pro Glu
65   70   75   80

Asp Xaa Ala Thr Tyr Tyr Cys Xaa Xaa Trp Ser Ser Asp Pro Phe Thr
            85   90   95

Phe Gly Xaa Gly Thr Lys Val Glu Ile Lys
            100   105

(2) INFORMATION FOR SEQ ID NO:10:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 116 amino acids
        (B) TYPE: amino acid
        (C) STRANDEDNESS: single
        (D) TOPOLOGY: linear

    (ii) MOLECULE TYPE: peptide

    (ix) FEATURE:
        (A) NAME/KEY: Region
        (B) LOCATION: one-of(1)
        (D) OTHER INFORMATION: /note= "Xaa is Glu, Gln or Asp."

    (ix) FEATURE:
        (A) NAME/KEY: Region
        (B) LOCATION: one-of(34)
        (D) OTHER INFORMATION: /note= "Xaa is Met, Ile, Val or Leu."

    (ix) FEATURE:
        (A) NAME/KEY: Region
        (B) LOCATION: one-of(49)
        (D) OTHER INFORMATION: /note= "Xaa is Ala or Ser."

    (ix) FEATURE:
        (A) NAME/KEY: Region
        (B) LOCATION: one-of(61,62,63)
        (D) OTHER INFORMATION: /note= "Xaa is any amino acid."

    (ix) FEATURE:
        (A) NAME/KEY: Region
        (B) LOCATION: one-of(64)
        (D) OTHER INFORMATION: /note= "Xaa is Val, Ala, Ile, Leu or
                    Met."

    (ix) FEATURE:
        (A) NAME/KEY: Region
        (B) LOCATION: one-of(65)
        (D) OTHER INFORMATION: /note= "Xaa is Arg, Lys or Gln."

    (ix) FEATURE:
        (A) NAME/KEY: Region
        (B) LOCATION: one-of(66)
        (D) OTHER INFORMATION: /note= "Xaa is Gly, Ala, Asp, Thr or
                    Ser."

    (ix) FEATURE:
        (A) NAME/KEY: Region
        (B) LOCATION: one-of(75)
        (D) OTHER INFORMATION: /note= "Xaa is Ser, Ala or Pro."

```
(ix)  FEATURE:
      (A)  NAME/KEY: Region
      (B)  LOCATION: one-of(78)
      (D)  OTHER INFORMATION: /note= "Xaa is Thr or Ser."

(ix)  FEATURE:
      (A)  NAME/KEY: Region
      (B)  LOCATION: one-of(84)
      (D)  OTHER INFORMATION: /note= "Xaa is Asn or Thr."

(ix)  FEATURE:
      (A)  NAME/KEY: Region
      (B)  LOCATION: one-of(116)
      (D)  OTHER INFORMATION: /note= "Xaa is Ala or Ser."


(xi)  SEQUENCE DESCRIPTION: SEQ ID NO:10:

Xaa Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1               5                  10                  15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe
            20                  25                  30

Gly Xaa His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
        35                  40                  45

Xaa Phe Ile Ser Ser Gly Ser Ser Thr Ile Tyr Tyr Xaa Xaa Xaa Xaa
    50                  55                  60

Xaa Xaa Arg Phe Ile Ile Ser Arg Asp Asn Xaa Lys Asn Xaa Leu Tyr
65                  70                  75                  80

Leu Gln Met Xaa Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
            85              .   90                  95

Ala Arg Pro Leu Pro Pro Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val
            100                 105                 110

Thr Val Ser Xaa
        115
```

64

WHAT IS CLAIMED IS:

1   1.   A monoclonal antibody having a binding site that
2   specifically binds to P-selectin and to E-selectin, said
3   antibody having an affinity for each of P-selectin and
4   E-selectin of at least 10^8 M^{-1}.

1   2.   The antibody of claim 1, wherein
2   the specific binding of the antibody to the P-selectin
3   inhibits binding of the P-selectin to a counterreceptor of
4   P-selectin; and
5   the specific binding of the antibody to the E-selectin
6   inhibits binding of the E-selectin to a counterreceptor of
7   E-selectin.

1   3.   The antibody of claim 2, wherein the
2   counterreceptors are expressed on an HL-60 cell or a
3   neutrophil.

1   4.   The antibody of claim 2 that competes with
2   antibody 5C7.29, ATCC accession number CRL 11640, for specific
3   binding to P-selectin and to E-selectin.

1   5.   The antibody of claim 2 that is a mouse
2   antibody.

1   6.   The antibody of claim 2 that is monoclonal
2   antibody 5C7.29, ATCC accession number CRL 11640.

1   7.   The antibody of claim 2 that is a Fab, Fab',
2   $F(ab')_2$, Fv fragment, or a single-chain antibody.

1   8.   The antibody of claim 2 that is a human
2   antibody.

1   9.   The antibody of claim 1 that does not
2   specifically bind to L-selectin.

1   10.   The antibody of claim 1 that specifically binds
2   to L-selectin.

1   11.   The antibody of claim 1 that recognizes an
2   epitope of E-selectin comprising amino acids Q_{21}, R_{22}, Y_{23},
3   T_{119}, and A_{120}.

1   12.   A humanized antibody that specifically binds to
2   P-selectin and inhibits the binding of the P-selectin to a
3   counterreceptor of P-selectin; and that specifically binds to
4   E-selectin and inhibits the binding of the E-selectin to a
5   counterreceptor of E-selectin, said antibody comprising a
6   humanized light chain variable region and a humanized heavy
7   chain variable region wherein
8   (1)   the humanized light chain variable region comprises
9   complementarity determining regions having amino acid
10   sequences from a non-human antibody light chain and comprises
11   a variable region framework sequence substantially identical
12   to a human light chain variable region framework sequence; and
13   (2)   the humanized heavy chain variable region comprises
14   complementarity determining regions having amino acid
15   sequences from a non-human antibody heavy chain, and comprises
16   a variable region framework sequence substantially identical
17   to a human heavy chain variable region framework sequence.

1   13.   The humanized antibody of claim 12 wherein the
2   humanized light chain variable region has a sequence
3   substantially identical to the sequence:
4   DIQMTQSPSS   LSASVGDRVT   ITCSASSSVP   YMHWYQQKPG
5   KAPKLLIYDT   SNLASGVPSR   FSGSGSGTSY   TLTISSLQPE
6   DFATYYCQQW   SSDPFTFGQG   TKVEIK   [SEQ ID NO:6]
7   and the humanized heavy chain variable region has a sequence
8   substantially identical to the sequence:
9   EVQLVESGGG   LVQPGGSLRL   SCAASGFTFS   SFGMHWVRQA
10   PGKGLEWVAF   ISSGSSTIYY   ADTVRGRFTI   SRDNSKNTLY
11   LQMNSLRAED   TAVYYCARPL   PPFAYWGQGT   LVTVSA
12   [SEQ ID NO:8].

1   14.   The humanized antibody of claim 13 wherein (a)

2   the humanized light chain variable region has the sequence:

3   $X_1IX_2X_3TQSPSS$ LSASVGDRVT   ITCSASSSX_{11}P   YX_{12}HWYQQKPG

4   KAPKLLIYDT   SN$X_{13}X_{14}X_{15}$GVPX_4R X_7SGSGSGTX_5X_6 TX_8TISSLQPE

5   DX_9ATYYC$X_{16}X_{17}$W   SSDPFTFGX_{10}G   TKVEIK [SEQ ID NO:9], wherein X_1

6   = D or Q; X_2 = Q or V; X_3 = M or L; X_4 = S or A; X_5 = S or D;

7   X_6 = Y or F; X_7 = F or I; X_8 = L or F; X_9 = F, I or A; X_{10} = Q,

8   G or S; X_{11} = V, I or L; X_{12} = M or L; X_{13} = any amino acid;

9   X_{14} = any amino acid; X_{15} = S or T; X_{16} = Q, N or H; and X_{17} =

10   Q, N or H; and (b) the humanized heavy chain variable region

11   has the sequence: X_3VQLVESGGG   LVQPGGSLRL   SCAASGFTFS

12   SFGX_7HWVRQA PGKGLEWVX_1F   ISSGSSTIYY $X_8X_9X_{10}X_{11}X_{12}X_{13}$RFTI

13   SRDNX_4KNX_5LY LQMX_2SLRAED TAVYYCARPL   PPFAYWGQGT   LVTVSX_6 [SEQ

14   ID NO:10]; wherein, X_1 = A or S; X_2 = N or T; X_3 = E, Q or D;

15   X_4 = S, A or P; X_5 = T or S; X_6 = A or S; X_7 = M, I, V or L; X_8

16   = any amino acid; X_9 = any amino acid; X_{10} = any amino acid;

17   X_{11} = V, A, I, L, M or F; X_{12} = R, K or Q; and X_{13} = G, A, D, T

18   or S.

1   15.   The humanized antibody of claim 13 wherein in

2   the humanized light chain variable region, X_{11} = V; X_{12} = M;

3   X_{13} = L; X_{14} = A; X_{15} = S; X_{16} = Q; and X_{17} = Q; and wherein in

4   the humanized heavy chain variable region, X_7 = M; X_8 = A; X_9

5   = D; X_{10} = T; X_{11} = V; X_{12} = R; and X_{13} = G.

1   16.   The humanized antibody of claim 13 wherein the

2   humanized light chain variable region has the sequence:

3   DIQMTQSPSS   LSASVGDRVT   ITCSASSSVP   YMHWYQQKPG

4   KAPKLLIYDT   SNLASGVPSR   FSGSGSGTSY   TLTISSLQPE

5   DFATYYCQQW   SSDPFTFGQG   TKVEIK   [SEQ ID NO:6]

6   and the humanized heavy chain variable region has the

7   sequence:

8   EVQLVESGGG   LVQPGGSLRL   SCAASGFTFS   SFGMHWVRQA

9   PGKGLEWVAF   ISSGSSTIYY   ADTVRGRFTI   SRDNSKNTLY

10   LQMNSLRAED   TAVYYCARPL   PPFAYWGQGT   LVTVSA

11   [SEQ ID NO:8].

1   17. The humanized antibody of claim 12 further
2 comprising light chain and heavy chain constant regions
3 substantially identical to human light chain and heavy chain
4 constant regions.

1   18. A purified nucleic acid segment encoding a
2 light or heavy chain variable region of the antibody of claim
3 2.

1   19. A purified nucleic acid segment encoding a
2 light or heavy chain variable region of the antibody of claim
3 12.

1   20. The purified nucleic acid segment of claim 19
2 further comprising a light chain or heavy chain constant
3 region substantially identical to a human light chain or heavy
4 chain constant region.

1   21. A stable cell line comprising:
2   a nucleic acid segment encoding the heavy chain of the
3 antibody of claim 2, the segment operably linked to a first
4 promoter to allow expression of the heavy chain;
5   a second nucleic acid segment encoding the light chain of
6 the antibody of claim 2, the second segment operably linked to
7 a second promoter to allow expression of the light chain;
8   wherein the stable cell line can produce the antibody of
9 claim 2.

1   22. A stable cell line comprising:
2   a nucleic acid segment encoding the heavy chain of the
3 antibody of claim 12, the segment operably linked to a first
4 promoter to allow expression of the heavy chain;
5   a second nucleic acid segment encoding the light chain of
6 the antibody of claim 12, the second segment operably linked
7 to a second promoter to allow expression of the light chain;
8   wherein the stable cell line can produce the antibody of
9 claim 12.

1   23.   A pharmaceutical composition comprising the
2   monoclonal antibody of claim 2.

3   24.   A pharmaceutical composition comprising the
4   monoclonal antibody of claim 12.

1   25.   A method of treating an inflammatory disease or
2   condition, comprising administering to a human patient a
3   therapeutically effective dose of the pharmaceutical
4   composition of claim 12.

1   26.   A method according to claim 25, wherein the
2   inflammatory disease or condition is selected from the group
3   consisting of ischemia-reperfusion injury, adult respiratory
4   distress syndrome, trauma, stroke, sepsis, psoriasis, and
5   autoimmune disease.

1   27.   The method of claim 26 wherein the inflammatory
2   disease or condition is ischemia-reperfusion injury after
3   myocardial infarction or stroke.

1   28.   The method of claim 27 further comprising the
2   step of administering a therapeutically effective dose of a
3   thrombolytic agent.

1   29.   A method of generating an antibody capable of
2   blocking E-selectin and P-selectin mediated functions, the
3   method comprising:
4   immunizing a mammal with P-selectin;
5   immunizing the mammal with E-selectin;
6   immortalizing B-cells from the mammal to obtain
7   immortalized cells producing antibodies; and
8   selecting an immortalized cell producing an antibody that
9   specifically binds to E-selectin and to P-selectin.

1   30.   A method of detecting E-selectin and P-selectin
2   bearing cells in a biological sample suspected of containing
3   the cells, the method comprising:

4   contacting the sample with the antibody of claim 2 to
5   form an immune complex with the E-selectin and P-selectin
6   bearing cells; and
7   detecting the presence of the immune complex to indicate
8   the presence of the cells.

1   31.   A method of detecting E-selectin and P-selectin
2   bearing cells in a biological sample suspected of containing
3   the cells, the method comprising:
4   contacting the sample with the antibody of claim 12 to
5   form an immune complex with the E-selectin and P-selectin
6   bearing cells; and
7   detecting the presence of the immune complex to indicate
8   the presence of the cells.

1   32.   A monoclonal antibody that specifically binds
2   to E-selectin and P-selectin, said antibody binding to the
3   same epitope of E-selectin as antibody 5C7.29, ATCC accession
4   number CRL 11640.

1   33.   The monoclonal antibody of claim 32, said
2   antibody further binding to the same epitope of P-selectin as
3   antibody 5C7.29, ATCC accession number.

FIG. 1A   **FIG. 1B**

FIG. 2A

FIG. 2B

FIG. 3A

FIG. 3B

Figure 4

Figure 5

Figure 6

% HL-60 Bound by Platelets

```
ATG GAT TTT CAA GTG CAG ATT TTC AGC TTC CTG CTA ATC AGT GCC TCA GTC ATA ATA TCC
 M   D   F   Q   V   Q   I   F   S   F   L   L   I   S   A   S   V   I   I   S
                              30                                          60

AGA GGA CAA ATT GTT CTC ACC CAG TCT CCA GCA ATC ATG TCT GCA TCT CCA GGG GAG AAG
 R   G   Q   I   V   L   T   Q   S   P   A   I   M   S   A   S   P   G   E   K
                              90                                         120

GTC ACC ATG ACC TGC AGT GCC AGC TCA AGT GTG CCT TAC ATG CAC TGG TAT CAG CAG AAG
 V   T   M   T   C   S   A   S   S   S   V   P   Y   M   H   W   Y   Q   Q   K
                             150                                         180

TCA GGC ACC TCC CCC AAA TTA TGG ATT TAT GAC ACA TCC AAT CTG GCT TCT GGA GTC CCT
 S   G   T   S   P   K   L   W   I   Y   D   T   S   N   L   A   S   G   V   P
                             210                                         240

GCT CGC TTC AGT GGC AGT GGG TCT GGG ACC TCT TAC TCT CTC ACA ATC AGC AGC ATG GAG
 A   R   F   S   G   S   G   S   G   T   S   Y   S   L   T   I   S   S   M   E
                             270                                         300

GCT GAA GAT GCT GCC ACT TAT TAC TGC CAG CAG TGG AGT AGT GAC CCA TTC ACG TTC GGC
 A   E   D   A   A   T   Y   Y   C   Q   Q   W   S   S   D   P   F   T   F   G
                             330                                         360

TCG GGG ACA AAG TTG GAA ATA AAG
 S   G   T   K   L   E   I   K
```

FIG. 7A

```
ATG GAC TCC AGG CTC AAT TTA GTT TTC CTT ATT TTA AAA GGT GTC CAG TGT GAT
 M   D   S   R   L   N   L   V   F   L   I   L   K   G   V   Q   C   D
                        30                                       60

GTA CGA CTG GTG GAG TCT GGG GGA GGT TTA GTG CAG CCT GGA GGG TCC CGG AAA CTC TCC
 V   R   L   V   E   S   G   G   G   L   V   Q   P   G   G   S   R   K   L   S
                        90                                      120

TGT GCA GCC TCT GGA TTC ACT TTC AGT AGC TTT GGA ATG CAC TGG GTT CGT CAG GCT CCT
 C   A   A   S   G   F   T   F   S   S   F   G   M   H   W   V   R   Q   A   P
                       150                                      180

GAT AAG GGG CTG GAG TGG GTC GCA TTC ATT AGC AGT GGC AGT ACC ATC TAC TAT GCT
 D   K   G   L   E   W   V   A   F   I   S   S   G   S   T   I   Y   Y   A
                       210                                      240

GAC ACA GTG AGG GGC CGA TTC ACC ATC TCC AGA GAC AGT CCC AAG AAC ACC CTG TTC CTG
 D   T   V   R   G   R   F   T   I   S   R   D   S   P   K   N   T   L   F   L
                       270                                      300

CAA ATG ACC AGT CTA AGG TCT GAG GAC ACG GCC ATG TAT TAC TGT GCA AGA CCT TTA CCC
 Q   M   T   S   L   R   S   E   D   T   A   M   Y   Y   C   A   R   P   L   P
                       330                                      360

CCG TTT GCT TAC TGG GGC CAA GGG ACT TTG GTC ACT GTC TCT GCA
 P   F   A   Y   W   G   Q   G   T   L   V   T   V   S   A
                       390
```

FIG. 7B

```
                                                          30                                                          60
ATG  GAT  TTT  CAA  GTG  CAG  ATT  TTC  AGC  TTC  CTG  CTA  ATC  AGT  GCC  TCA  GTC  ATA  ATA  TCC
 M    D    F    Q    V    Q    I    F    S    F    L    L    I    S    A    S    V    I    I    S

                                                          90                                                         120
AGA  GGA  GAT  ATT  CAA  ATG  ACC  CAG  TCT  CCA  TCT  AGC  TTA  TCT  GCA  TCT  GTA  GGG  GAT  AGG
 R    G    D    I    Q    M    T    Q    S    P    S    S    L    S    A    S    V    G    D    R

                                                         150                                                         180
GTC  ACC  ATA  ACC  TGC  AGT  GCC  AGC  TCA  AGT  GTG  CCT  TAC  ATG  CAC  TGG  TAT  CAG  CAG  AAG
 V    T    I    T    C    S    A    S    S    S    V    P    Y    M    H    W    Y    Q    Q    K

                                                         210                                                         240
CCA  GGC  AAA  GCC  CCC  AAA  TTA  TTG  ATT  TAT  GAC  ACA  TCC  AAT  CTG  GCT  TCT  GGG  GTA  CCT
 P    G    K    A    P    K    L    L    I    Y    D    T    S    N    L    A    S    G    V    P

                                                         270                                                         300
TCT  CGC  TTC  AGT  GGC  AGT  GGG  TCT  GGG  ACC  TCT  TAC  ACT  CTC  ACA  ATC  AGC  AGC  CTG  CAG
 S    R    F    S    G    S    G    S    G    T    S    Y    T    L    T    I    S    S    L    Q

                                                         330                                                         360
CCT  GAA  GAT  TTT  GCC  ACT  TAT  TAC  TGC  CAG  CAG  TGG  AGT  AGT  GAC  CCA  TTC  ACG  TTC  GGC
 P    E    D    F    A    T    Y    Y    C    Q    Q    W    S    S    D    P    F    T    F    G

CAG  GGG  ACA  AAG  GTG  GAA  ATA  AAA
 Q    G    T    K    V    E    I    K
```

FIG. 8A

ATG GAC TCC AGG CTC AAT TTA GTT TTC CTT GTC CTT ATT TTA AAA GGT GTC CAG TGT GAA 60
 M   D   S   R   L   N   L   V   F   L   V   L   I   L   K   G   V   Q   C   E
                            30

GTG CAA CTG GTG GAG TCT GGG GGA GGT TTA GTG CAG CCT GGA GGG TCC CTT CGT CTC TCC 120
 V   Q   L   V   E   S   G   G   G   L   V   Q   P   G   G   S   L   R   L   S
                            90

TGT GCA GCC TCT GGA TTC ACT TTC AGT AGC TTT GGA ATG CAC TGG GTT CGT CAG GCT CCT 180
 C   A   A   S   G   F   T   F   S   S   F   G   M   H   W   V   R   Q   A   P
                            150

GGT AAG GGG CTG GAG TGG GTC GCA TTC ATT AGC AGT GGC TCG ACC ATC TAC TAT GCT 240
 G   K   G   L   E   W   V   A   F   I   S   S   G   S   T   I   Y   Y   A
                            210

GAC ACA GTG AGG GGC CGA TTC ACC ATC TCC AGA GAC AAT TCT AAG AAC ACC CTG TAT CTG 300
 D   T   V   R   G   R   F   T   I   S   R   D   N   S   K   N   T   L   Y   L
                            270

CAA ATG AAC AGT CTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT GCA AGA CCT TTA CCC 360
 Q   M   N   S   L   R   A   E   D   T   A   V   Y   Y   C   A   R   P   L   P
                            330

CCG TTT GCT TAC TGG GGC CAA GGG ACT TTG GTC ACT GTC TCT GCA
 P   F   A   Y   W   G   Q   G   T   L   V   T   V   S   A
   390

FIG. 8B

Figure 9

Figure 10

Figure 11A

Figure 11B

Figure 12

Figure 13

INTERNATIONAL SEARCH REPORT

A.	CLASSIFICATION OF SUBJECT MATTER

IPC(6) :Please See Extra Sheet.

US CL :Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B.	FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. :   424/133.1, 136.1, 143.1, 144.1, 152.1, 172.1; 435/172.2., 240.27; 530/387.3; 536/23.53

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, DIALOG, BIOSIS, EMBASE, MEDLINE, CA, WPI

search terms: berg, p-selectin, e-selectin, antibod?, cross-reactive, epitope?

C.	DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	J. CELL BIOL., VOLUME 120, NUMBER 5, ISSUED MARCH 1993, D.V. ERBE ET AL., "P- AND E-SELECTIN USE COMMON SITES FOR CARBOHYDRATE LIGAND RECOGNITION AND CELL ADHESION", PAGES 1227-1235, SEE ENTIRE DOCUMENT.	1-33
X	AM. J. PATHOL., VOLUME 144, NUMBER 3, ISSUED MARCH 1994, A. SEEKAMP ET AL., "ROLE OF SELECTINS IN LOCAL AND REMOTE TISSUE INJURY FOLLOWING ISCHEMIA AND REPERFUSION", PAGES 592-598, SEE ENTIRE DOCUMENT.	1-33
X	IMMUNOL. TODAY, VOLUME 14, NUMBER 10, ISSUED 1993, A.J.H. GEARING ET AL., "CIRCULATING ADHESION MOLECULES IN DISEASE", PAGES 506-512, SEE ENTIRE DOCUMENT.	1-33

☐	Further documents are listed in the continuation of Box C.	☐	See patent family annex.

*	Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance		
"E"	earlier document published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed	"&"	document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
17 AUGUST 1995	07 SEP 1995

Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT . Washington, D.C. 20231	Authorized officer PHILLIP GAMBEL
Facsimile No. (703) 305-3230	Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*

A. CLASSIFICATION OF SUBJECT MATTER:
IPC (6):

A61K 39/395; C07K 16/00, 16/18, 16/28, 16/46; C12N 5/10, 5/16, 15/13; C12P 21/08

A. CLASSIFICATION OF SUBJECT MATTER:
US CL :

424/133.1, 136.1, 143.1, 144.1, 152.1, 172.1; 435/172.2., 240.27; 530/387.3; 536/23.53